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ABSTRACT 
Chemotherapeutics are the major treatment options for cancer. Although we cannot 
underestimate the importance of the chemotherapeutic drugs, their systemic toxicity is an 
important limiting factor for their use. Therefore, altering the biodistribution of the therapeutics 
can be an important step in treating the cancer patients. Thus, there is a growing interest in 
developing smart, targeted, stimuli responsive, drug delivery vehicles employing nanotechnalogy. 
The vehicles are often engineered to deliver the theranostics to the tumor microenvironment 
(extracellular matrix) or intracellular environment (e.g. cytosol, nucleus, mitochondria). The 
physiochemical changes in the cancerous tissues (e.g. leaky vasculature, proteins overexpression 
on the cell surface, overexpression of proteolytic enzymes, increased reducing agents 
concentration, decreased pH, and hypoxia) offer tremendous opportunities for selectively targeting 
the malignancies. Polymersomes are robust polymeric vesicles which have shown promising drug 
delivery capabilities. Both hydrophilic and hydrophobic compounds can be loaded to the vesicles. 
The polymersome’s building blocks can be chemically manipulated to provide them with the 
optimum release profile. Furthermore, the surface of the polymersomes can be decorated with 
targeting moieties such as peptides, antibodies, or small molecules. We have developed smart, 
targeted, stimuli responsive polymersomes to combat pancreatic and prostate cancers. 
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1. INTRODUCTION1 AND DISSERTATION ORGANIZATION 
1.1. Drug Delivery Using Nanoparticles 
Nanotechnology has revolutionized the science and especially medicine. The special 
physiochemical properties of nanoparticles, e.g., high surface area to mass ratio, small size, and 
ability to carry materials are attractive to scientists around the world.1 It was believed in early 
1970s that suspensions couldn’t be administered via intravenous route because of the possible 
problems like embolism.2 However, the nanotechnology and ability to prepare tens to hundreds of 
nanometer diameter particles has changed this belief.  
In medicine, the nanoparticles have been used as “theranostic” agents. In drug delivery, an 
appropriate nanoparticle has high loading capacity, stability, appropriate release profile, 
targetability, biocompatibility, and biodegradability.3 To confer biocompatibility and 
biodegradability to the nanoparticles, various materials from natural origin (e.g., chitosan,4 
dextran5, phospholipids6) or synthetic (e.g., poly lactic acid7, polyethylene glycol7, poly 
caprolactone8) have been used. Different loading strategies are reported for increasing the 
nanoparticles loading capacity (e.g., passive or active loading3). Increasing the loading capacity 
improves the efficacy of the formulations by decreasing the amount of carrier materials to the 
patient body. This limits the undesired side effects arising from the carrier itself. Targeted drug 
delivery is an accepted strategy to increase the therapeutic index of the nanotherapeutic 
formulations. Targeting the nanoparticles to a special tissue or organ can assist in decreasing the 
adverse effects on healthy cells or tissues.  Chemical conjugations (e.g., Click chemistry) has 
                                                 
 
1 This section is coauthored by Tayebeh Anajaﬁ and Sanku Mallik. Tayebeh had primary responsibility to write the 
review paper. Dr. Mallik advised and verified the manuscript. 
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provided a spectacular opportunity to conjugate targeting moieties (e.g., small molecules, peptides, 
antibodies) to the surface of nanoparticles.7   
Several nanoparticles have been used for drug delivery. Liposomes,9 polymersomes,7 
micelles,10 silica nanoparticles11 are a few promising nanocarriers. In this paper-based thesis, we 
have focused on polymersomal formulations because of their stability, high loading capacity, and 
the ability for functionalization with different moieties. I have used my review paper on 
polymersomes for the following paragraphs of the introduction. 
1.2. Polymeric Nanovesicles 
The idea of polymeric vesicles (polymersomes) germinated during a discussion about the 
phase behavior of di-block co-polymers in 1994.12 This discussion was followed by preparing 
nano-sized polymer vesicles using a specific di-block co-polymer (polyethyleneoxide-
polyethylethylene; f EO = 0.39, Mw = 3,600).13 These vesicles were proven to be more robust and 
less water permeable compared to phospholipid vesicles or liposomes.13 Since then, several 
research laboratories have been studying polymersomes for different purposes, including 
drug/gene delivery, diagnosis, bioreactors, and cell/viral capsid mimicking.14, 15 
These hollow vesicles (Figure 1.1 A) consist of a watery interior that is separated from the 
aqueous surrounding media by an amphiphilic polymer bilayer. The thickness of the bilayer (5-30 
nm) usually causes a more robust and impermeable wall compared to the liposomal structures (3-
5 nm).14 This feature depends on the molecular weights of the co-polymers used in the 
polymersomes. It has been observed that the membrane thickness (d) is proportional to MW0.55. 
Among the biomedical applications for polymersomes, drug/gene delivery holds the most 
promise due to the tunable chemistry of the block co-polymers (including the versatility of 
monomers and the possibility to change block polymers’ molar mass and percentage), their low 
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critical aggregation concentration, and the robustness of the polymersomes’ bilayer. The latter 
characteristic can increase the stability of encapsulated compounds for a long time.16 The 
polymersomes’ hollow core can be used to encapsulate hydrophilic compounds, and the bilayer 
can be dedicated for loading the hydrophobic compounds. In such a scenario, the combination 
therapy (Figure 1.1 B) and diagnostic purposes can be achieved using polymersomes.     
Designing clinically applicable polymersomes has been a challenging area in the last 
several decades. Herein, we elaborate on the recent developments of biocompatible polymersomes 
as targeted delivery vehicles for cancer therapy.  
 
Figure 1.1. Polymersomes. (A) Transmission electron microscopic image of a polymersome 
constructed using poly (ethylene glycol)-b-poly (lactic acid) copolymer (The scale bar shows 20 
nm). (B) Schematic illustration of combination cancer therapy using a polymersome. The 
hydrophilic core of the polymersome is loaded by a conventional, hydrophilic, anti-cancer drug 
(Doxorubicin), and a hydrophobic chemotherapy drug (Paclitaxel) is incorporated in the 
hydrophobic bilayer of the polymersome.  
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1.2.1. Polymersomes Preparation 
Typically, polymersomes are prepared from amphiphilic, linear block co-polymers.17 The 
ratio of the hydrophilic part to the total mass of the co-polymers (f value) is a determinant factor 
in the formation of different nano-structures.17, 18, 19 If the f value is higher than 50%, the formation 
of micelles is possible, and if the value is 40-50%, worm-like structures are more likely. However, 
if the f value is between 25% and 40%, which is similar to natural phospholipids, the formation of 
vesicles is more favorable17, 19 (Figure 1.2). In addition to linear block co-polymers, mictoarm 
polymers have been used as alternative building blocks for polymersomes.20, 21 These Y-shaped, 
complex polymers not only have a greater ability to form polymersomes, but are also able to mimic 
the phospholipid structures.20, 21    
Several methods have been used to prepare polymersomes, including the solvent-exchange 
method, film rehydration, electroformation,13 and the double-emulsion strategy.22 
Electroformation has been used to construct giant polymersomes. Double emulsion (which have 
been prepared using capillary microfluidics) is a reliable method for preparing polymersomes with 
acceptable monodispersity in size and uniformity in the bilayer membrane. Among these methods, 
the solvent-exchange method is widely used for its ease, reproducibility, and control over the size 
of nano-particles. Although filter extrusion has been used to decrease the polydipersity index of 
liposomes, this method seems to be a very time-consuming and difficult approach for 
polymersomes, even at elevated temperatures due to the polymersome membrane’s robustness. 
1.2.2. Drug Encapsulation in Polymersomes 
Drug loading capacity is one of the important factors to be considered in any nano-delivery 
systems’ preparation. If the encapsulation efficiency is not high enough, higher amounts of the 
nano-particles need to be injected (to reach the therapeutic window), leading to the introduction of 
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a higher fraction of polymer (in case of polymersomes) in the patient’s body. Both passive and 
active (remote) loading strategies have been utilized for encapsulating hydrophobic or hydrophilic 
compounds in the polymersomes. For passive loading, hydrophobic compound of interest is 
solubilized/dispersed in an organic solvent along with the polymers used for the polymersomes. 
Hydrophilic drugs or imaging agents are usually added to the aqueous buffer during polymersome 
preparation. However, due to the low water solubility of some compounds, and the pivotal need 
for high drug loading capacity, active liposomal loading procedures (e.g. salt and pH gradient) 
have been adapted for polymersomes. Preparation of paclitaxel encapsulated polymersomes (from 
pre-formed vesicles) revealed that drug loading efficiency is about 10-fold higher than that of 
liposomes. The higher efficiency is attributed to the presence of thicker hydrophobic membrane in 
polymersomes’ structure compared to the liposomal lipid bilayer.23 The hydrophilic, cytotoxic 
drug, doxorubicin, is encapsulated inside the polymersomes’ hollow core using either a pH 
gradient23, 24, 25 or an ammonium sulfate gradient.26 The encapsulation efficiency for polymersomes 
was similar to the corresponding liposomal formulations. Due to the stability and reduced leakage 
of incorporated compounds, polymersomes have the potential to be more acceptable drug carriers 
compared to liposomes. 
1.2.3. Biomedically Translatable Polymersomes 
Ideal polymersomes with biomedically applicable properties need to have enough loading 
capacity for the active ingredients. Also, these polymersomes should be robust enough to protect 
the payload from unexpected release. These nano-structures should have a long circulation time 
and low renal clearance rate while the cargo release needs to be controllable. In addition, 
specificity toward the desired target site as well as presenting no or minimum immunogenicity are 
important criteria. Any premature release of the encapsulated drug can increase the risk of side 
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effects, especially in the case of cytotoxic anti-cancer drugs. However, reduced therapeutic 
efficacy and drug resistance could be expected as a consequence of slow drug release. Considering 
these facts, many studies focus on designing polymersomes with improved biodegradability and 
biocompatibility. 
 
Figure 1.2. Schematic representation of spherical/worm-like micelles and polymersomes. 
Changing the f value of the block co-polymers determines the formation of different structures. 
 
1.2.3.1. Biocompatibility 
To increase the polymersomes’ biocompatibility, interactions with blood components 
should be adjusted to be at minimum, and the vesicles should be guided toward the target sites. 
There are several approaches, including PEGylation and using targeting moieties, to improve the 
pharmacodynamic and pharmacokinetic properties of theranostic delivery systems. 
1.2.3.1.1. PEGylation 
The Enhanced Permeability and Retention (EPR) effect is one of the mechanisms (passive 
targeting) used for delivering drugs to various cancer tumors. With most tumors, the presence of a 
non-organized, leaky vasculature along with gaps of 100 nm – 2 µm have been established. 
Therefore, nano-particles with a mean size less than 200 nm are able to extravasate through these 
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leaky, imperfect vasculatures with most cancers. A poorly developed lymphatic system in the 
tumor tissues helps retain nano-particles in tumor area. However, it should be noted that blood 
flow to the tumor site is also restricted in comparison with normal organs. Hence, having a good 
amount of nano-particle accumulation requires a long circulation time which, itself, is confined by 
the body’s immune system.  
The innate immune system is constantly monitoring the body’s environment, searching for 
foreign materials, including pathogens and other exogenous particles such as drug-delivery 
systems. Therefore, one of the important challenges with drug-delivery approaches is the fate of 
the carrier and its ability to escape from the reticuloendothelial system’s uptake. If the nano-
carrier’s surface is not covered to evade the innate immune system, blood proteins (e.g., antibodies 
and complement system) can surround the carrier (opsonization) and make it engulfable by 
phagocytes in the reticuloendothelial system’s (RES) organs. For example, Kupffer cells (resident 
liver macrophages) are able to distinguish and process the opsonized foreign particles using 
scavenger receptors. As a result, the half-life of the drug-delivery systems decreases drastically, 
and more than 50% of the injected dose is usually cleared shortly after administration.27 
Furthermore, accumulation of the drug-delivery systems by phagocytes in secondary immune 
organs such as the spleen and liver increases the chance of organ toxicity, decreasing the drug’s 
therapeutic index (Figure 1.3). Hence, different hydrophilic polymers [e.g., poly (ethyleneglycol) 
(PEG) and N-(2-hydroxypropyl) methacrylamide (HPMA)]28 and polysaccharides (e.g., heparin)29 
have been used to sterically hinder the opsonization process by the white blood cells. PEG with no 
charge and a non-biodegradable30 characteristic is the most-studied polymer that contributes to the 
stealth properties of drug-delivery systems. 
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The PEG surface concentration is also important for imparting stealth properties to the 
nano- carriers. It has been shown that increasing the PEG surface concentration weakens the 
protein adsorption on the nano-particles’ surface.31 Another determinant factor which affects the 
vectors’ camouflage is the size of the PEG polymer. For example, a PEG brush with a molecular 
weight of more than 3,400 Da has the highest effect to decrease human plasma protein adsorption 
on the surface of polystyrene particles.31 Electrostatic properties of the vehicle surface area are 
another determinant factor that should be considered. A slightly positive or negative charge may 
increase the half-life of drug-delivery systems. However, a highly charged surface should be 
avoided on the carriers because it not only confers toxicity,32 but also decreases the nano-particle 
circulation time by increasing the amount of hepatic uptake.33  
It should be noted that the stealth properties rendered by the hydrophilic polymers are only 
effective for a limited time. Eventually, proteins adsorb on the nano-carriers’ surface, and 
clearance of polymersomes is unavoidable.17 In addition, a long circulation time increases the 
drug’s side effects in healthy tissues27 and may even initiate immune reactions toward the nano-
particles.34 To further complicate the situation, PEGylation not only decreases the protein 
adsorption, but also impairs the nano-carriers’ interaction with the cells. An interesting solution 
for this problem is to use sheddable PEG groups.27, 35 With this strategy, PEG helps to achieve a 
long circulation time; however, the layer sheds after extravasation and increases the chance of the 
cellular uptake. The other strategy to circumvent the low cellular uptake of PEG-conjugated nano- 
particles is to conjugate cell-targeting moieties to the PEG’s terminal hydroxyl group. 
1.2.3.1.2. Targeted Drug Delivery 
Another strategy to alter the biodistribution is active targeting via the incorporation of 
suitable moieties on the polymersomes’ surface. Active targeting can increase the vesicles 
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’selective cellular uptake and decrease the unwanted toxicity to nearby cells/tissues. Polymersome 
functionalization has been carried out using proteins (including monoclonal antibodies and 
antibody fragments), peptides, small organic molecules, carbohydrates, and aptamers. 
Functionalized polymersomes have been used for theranostic purposes with different diseases such 
as cancers, inflammations, and brain-related disorders (Table 1.1). 
 
Figure 1.3. Schematic distribution of polymersomes after injection. (A) Stealth polymersomes can 
evade the RES and accumulate in the tumor tissue as a result of the EPR effect. In this case, 
systemic toxicity decreases, and the drug’s therapeutic index increases. (B) Non-stealth 
polymersomes can be recognized by the RES and cleared from the blood rapidly. Tumor 
accumulation is not lower than that for RES organs such as the liver and spleen. In this case, 
systemic toxicity is an important concern.  
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Table 1.1. Polymersomes for targeted theranostic delivery. 
Targeting 
moiety 
Target site Polymersomes’ 
building block 
Drug/Imaging 
agent loaded 
Application  Ref. 
Trastuzumab Human 
Epidermal 
Growth Factor 
Receptor-2 
(HER2) 
Poly (trimethylene 
carbonate)- b-
poly(glutamic 
acid) 
Superparamagnetic 
iron oxide 
nanoparticles 
(USPIOs; γFe2O3) 
Targeting and 
imaging of 
breast-cancer 
bone metastasis  
36 
Anti-EGFR 
antibody 
Epidermal 
Growth Factor 
Receptor 
(EGFR) 
Methoxy 
poly(ethylene 
glycol) (mPEG)-
Gly-Phe-Leu-Gly-
Phe-poly(D,L-
lactide) 
Acridine orange Targeted drug 
delivery to the 
breast-cancer 
cells 
37 
Anti-ICAM-
1 antibody 
Intercellular 
Adhesion 
Molecule-1 
(ICAM-1) 
Poly(ethylene 
oxide) (PEO)-b-
polybutadiene 
 
 –  
 
Targeting the 
inflammatory 
tissues 
38 
Anti-HIgG 
antibody/  
Anti-HSA 
antibody  
Human IgG 
(HIgG)/ 
Human Serum 
Albumin 
(HSA) 
poly(ethylene 
glycol) (PEG)- b-
poly(D,L-1actic 
acid) 
Carboxyfluorescein Theranostic 
targeting 
39 
Trastuzumab HER2 poly(dimethylsilo
xane)- 
b-poly(2-
methyloxazoline) 
 
– 
Theranostic 
delivery to the 
SKBR3 human 
breast-cancer 
cells 
40 
Anti-
tansferrin 
receptor 
antibody 
(OX26) 
Transferrin 
receptor 
PEG-b-poly(ε-
caprolactone) 
NC-1900 / 
Coumarin-6 
Brain drug 
delivery 
41 
Tet1 peptide Trisialoganglio
side 
clostridial 
toxin receptor 
on neurons 
poly(ε-
caprolactone)-b-
PEG 
Carboxy cyanine 
dye DiI 
Drug delivery to 
the cochlear 
nerve 
42 
PR_b 
peptide 
α5β1 integrins PEO-b-
poly(butadiene)  
TNFα Drug delivery to 
prostate 
cancer cells 
43 
RGD- 
containing 
peptide 
Integrin 
adhesion 
receptors 
PEO-b-poly(g-
methyl-3-
caprolactone) 
 
– 
Cell penetration 
of theranostics 
44 
RGD- 
containing 
peptide 
Integrin 
adhesion 
receptors 
PEG-b-poly(2-
hydroxyethyl 
aspartamide) 
substituted with 
octadecyl chains 
FITC-dextran Cell penetration 
of theranostics 
45 
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Table 1.1. Polymersomes for targeted theranostic delivery (continued).  
Targeting 
moiety 
Target site Polymersomes’ 
building block 
Drug/Imaging 
agent loaded 
Application Ref. 
Des-octanoyl 
ghrelin 
Des-octanoyl 
ghrelin 
binding sites 
on blood-brain 
barriers 
poly(carboxyl 
ethylene glycol-g-
glutamate)-co-
poly(distearin-g-
glutamate) 
Doxorubicin / 
Cy5.5 
Blood-brain 
barrier (BBB) 
theranostic 
delivery 
46 
Folate & 
des-octanoyl 
ghrelin 
Folate receptor 
& Des-
octanoyl 
ghrelin 
binding sites 
on blood-brain 
barriers 
poly(ethylene 
glycol)-g-
glutamate)-co-
poly (distearin-g-
glutamate) 
Met-enkephalin / 
Coumarin-6 / 
Cy5.5 
Penetrating and 
targeting  
brain-cancer 
therapeutics 
47 
sLex & 
anti-ICAM-1 
antibody 
P/E selectin & 
ICAM-1 
poly(1,2 
butadiene)-b-
poly(ethylene 
oxide) 
Porphyrin, PZn2 Monitoring 
inflammatory 
diseases 
12, 48 
Lactoferrin/ 
Transferrin  
Lipoprotein 
receptor-
related 
protein (LRP)/ 
transferrin 
receptor 
Poly (butadiene-b-
ethylene oxide)+ 
PEG-b-lactic acid) 
(PEG-PLA)+ 
maleimide- 
PEG-PLA 
Coumarin-6 Brain delivery 
 
49 
Lactoferrin LRP mPEG-poly(ε-
caprolactone) + α-
carboxyl 
poly(ethylene 
glycol)-poly(3-
caprolactone)/ 
PEG-poly  
(lactide)  
Doxorubicin / 
Tetrandrine / DiR / 
Coumarin-6 
BBB and glioma 
targeting 
50, 51 
 
Overexpression of various cell surface receptors in malignancies and other disorders (such 
as inflammations) has been used for designing theranostic delivery systems. For instance, the 
expression of epidermal growth factor receptor increases on the cell surface for  breast, colorectal, 
and lung cancers.52 Hence, the anti-HER2 receptor antibody (trastuzumab) has been used to 
specifically target cancer cells (breast cancer cells metastasized to the bone) and to deliver contrast 
agents for magnetic resonance imaging that employs polymersomes.36 Immobilizing different 
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antibodies is an interesting strategy, and several researchers have used this approach to target the 
proper cells/tissues. In this scenario, the antibody is usually immobilized via a covalent bond on 
the distal end of PEG block to avoid steric hindrance and to promote specific binding. Using 
antibodies as targeting agents has some disadvantages. These rather-large proteins are mostly 
immunogenic, and multi-functionalization of one carrier using antibodies is not favorable because 
of the antibodies’ large size. In addition, developing monoclonal antibodies is fairly expensive and 
time consuming.   
The other widely used targeting agents are peptides. Peptides are smaller and less 
immunogenic than antibodies, and attaching several peptides on the surface of a single 
polymersome is possible. Like antibodies, some peptides (e.g., Tet-142 and PR_b43) can be used to 
target a specific cell’s surface receptors or molecules. Moreover, some peptides, such as the 
transactivator of transcription (TAT, derived from the human immunodeficiency virus), and many 
other chimeric peptides, such as transportan,53 are known as cell-penetrating peptides. Some 
peptides guide the carriers toward subcellular compartments such as the nucleus and mitochondria. 
For instance, a heptapeptide derived from the Simian virus SV40 T-antigen has been used to 
construct nuclear-targeted delivery systems. These rather-new, nuclear-targeted drug-delivery 
systems are promising approaches that can increase drug efficacy, especially in terms of cancer 
therapy,54 because they are targeted toward the cell nucleus which contains genetic material. 
However, there are many barriers that the carrier should overcome to reach the nucleus.  
Carbohydrates play important roles with several biological processes, such as fertilization, 
cell-cell interactions, immune response, and signal transduction.55 Hence, polymersomes that are 
conjugated to carbohydrates can be used for the targeted delivery of drugs/imaging agents. For 
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example, sialyl Lewisx (sLex), a carbohydrate which binds to selectins, has been conjugated to 
polymersomes as a way of targeting the inflammatory tissues.12, 48 
Small molecules are sometimes are preferred as targeting groups because of their diversity, 
low molecular weight, small size, low immunogenicity, and inexpensiveness.56 For example, folate 
(Vitamin B6) is a small, organic molecule that has been widely used for targeted delivery systems 
because of the folate receptor’s  overexpression on the cells’ surface with cancers of the ovary,57, 
58  urinary bladder,59 lung,60 breast,61 and colon.62 
1.2.3.2. Biodegradability 
One drawback of polymersomes is the slow content release due to the robust and stable 
bilayer membrane.25, 63 To control the drug release and increase the drug’s bioavailability at the 
target site, stimuli-responsive polymersomes have been used extensively. These smart nano-
structures can receive, transfer, and respond to stimuli effectively. Both external and internal 
stimuli have been tested for triggering the cargo release. External stimuli can be light64 or a 
magnetic field,65 whereas pH,20, 66, 67 temperature,68 and redox potential19 are examples of internal 
stimuli. Using internal stimuli appears to be easier, cheaper, and more applicable.16 Table 1.2 
illustrates recently studied biodegradable polymersomes and their stimuli.  
1.2.3.2.1. Redox-Responsive Polymersomes 
Redox potentials are different for the intra/extracellular environments, and this difference 
tends to be augmented with the solid tumors of ovary, breast, lung, and head-and-neck cancers.69  
The redox potential is controlled by the concentration of glutathione (GSH, L-γ-glutamyl-L-
cysteinylglycine, a tripeptide), free cysteine, and free homocysteine. Although free cysteine and 
homocysteine have roles in redox equilibria, GSH has been used more frequently as a stimulus for 
triggered content releases from polymersomes. GSH is the most prevalent reduced thiol source, 
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and there is a large inherent heterogeneity for intracellular (0.5-10 mM) and extracellular (10-40 
µM) GSH concentrations. Hence, extracellular fluid is, naturally, an oxidizing environment. Both 
the extracellular oxidative environments70 and intracellular reductive environments71 have been 
utilized for polymersomes’ drug release.   
Table 1.2. Biodegradable polymersomes. 
PEG-S-S-PLA: poly (ethylene glycol)-b-poly (lactic acid); PEG–PTMBPEC: poly (ethylene 
glycol)-b-poly (2,4,6-trimethoxybenzylidenepentaerythritol carbonate); mPEG-b-(polyHis)2-CL: 
methoxy poly (ethylene glycol)-b-poly (L-histidine)-cholesterol incorporated; PEG-PTTMA-
PAA: poly (ethylene glycol)-b-poly (trimethoxybenzylidene tris(hydroxymethyl)ethane 
methacrylate)-b-poly (acrylic acid); PEG-PAA-PNIPAM: poly (ethylene glycol)-b-poly (acrylic 
acid)-b-poly (N-isopropylacrylamide); PTMC-b-PGA: Poly (trimethylene carbonate)-block-poly 
(L-glutamic acid); PEG-2NPA-PLA: poly (ethylene glycol)-2-nitrophenylalanine-poly (lactic 
acid); PMCL-ONB-PAA: poly (methyl caprolactone)-O-nitrobenzyl-poly (acrylic acid); and 
mPEG-pep-PDLLA: methoxy poly (ethylene glycol)-Gly-Phe-Leu-Gly-Phe- poly (D,L-lactide) 
 
Different strategies have been used to construct redox-sensitive drug carriers. Bioreducible 
polymersomes that possess disulfide bonds respond to the redox potential changes by reversible 
bond breakage. The number and location of the incorporated disulfide bonds allow fine-tuning of 
the release property from the vesicles. A typical composition that has been used widely for 
preparing redox-sensitive micelles74 and liposomes75 has been successfully implemented with 
polymersomes.19 These co-polymers contain a disulfide bond to connect the hydrophobic and 
Block co-polymer Description Release stimulus Response  Ref. 
PEG-S-S-PLA – Redox potential Bond cleavage 19 
PEG–PTMBPEC – pH Hydrolysis  66 
mPEG-b-(polyHis)2 
-CL 
Cholesterol 
incorporated 
pH Hydrophobic/ hydrophilic 
transition (structural 
transition) 
20 
PEG-PTTMA-PAA – pH Hydrolysis 67 
PEG-PAA PNIPAM Cystamine-
crosslinked 
Temperature & 
reduction 
Formation/deformation 68 
PTMC-b-PGA 
  
Polymersomes 
loaded with γ-
Fe2O3 
Magnetic field  Local hyperthermia 65 
PEG-2NPA-PLA – Light Peptide bond cleavage 64 
PMCL-ONB-PAA – Light Cleavage of linker 72, 73 
mPEG-pep-PDLLA – Enzyme (Cathepsin 
B) 
Peptide cleavage 37 
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hydrophilic polymers. Reductive conditions destabilize the formulation and trigger the release of 
the encapsulated payload. Crosslinked polymersomes display increased stability and, at the same 
time, are responsive to a reducing environment.76 Although the disulfide bond in the 
polymersomes’ backbone increases the drug release in the reducing environments, premature 
payload leakage may occur due to prolonged circulation with low concentrations of reducing 
agents in the blood which may decrease the therapeutic efficacy of the redox-sensitive 
polymersomes.  
1.2.4. Pharmacokinetic Properties of Polymersomes 
   The fate of the pharmaceutical agents after administration are determined by measuring 
their pharmacokinetic properties. However, polymersomes are new drug carriers, and not many 
detailed pharmacokinetic animal studies are reported (the reported results are summarized in Table 
1.3). It should be noted that a drug’s pharmacokinetic properties are related to the carrier chemistry. 
A comparison of the pharmacokinetic properties of PolyDoxoSomes (doxorubicin loaded 
polymersomes) with that of LipoDox (commercially available liposomal doxorubicin)77 is 
reported. PolyDoxoSome’s lower AUC (568 versus 229 μg h/mL), and shorter t1/2 (22 versus 35 
h) were advantageous for decreasing the dose related toxicities and side effects. Although the AUC 
and t1/2 values were different, the therapeutic efficacy of the PolyDoxoSome was comparable to 
that of the LipoDox. Another study compared the pharmacokinetics of AmbiSome (liposomal 
amphotericin B) and amphotericin-B-loaded polymersomes.78  A Lower AUC value was observed 
for the polymersomes (11,354 versus 62, 219 ng h/ mL), due to the direct delivery of the drugs to 
the target tissues. However, higher t1/2 (74 versus 27 h) was reported for the polymersomes, due to 
the slow release of the encapsulated drugs. The polymersomal formulations were deemed to be 
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better for treating fungal infections due to the longer circulation of these drug-loaded nano-
vesicles.  
Paper information: Polymersome-based drug-delivery strategies for cancer therapeutics 
(Ther. Deliv. (2015) 6(4), 521–534).3 
https://www.ncbi.nlm.nih.gov/pubmed/25996048 
1.3. Organization of the Thesis 
In an effort to search for more effective treatments (higher therapeutic index and lower 
systemic toxicity) for pancreatic cancer, we have prepared two different polymersomal 
formulations which are targeted toward nucleus of pancreatic cancer cells (Chapters 2 and 3). 
Nucleus is the largest organelle in the cells and contains the genetic materials79. Hence, delivering 
the drugs directly to the nucleus can increase the drug’s efficiency. Both polymersomal 
formulations are stable in the extracellular environment and in the cytoplasm. However, in the 
presence of high concentration of reducing agents in the cancer cell’s nuclei, their bilayer structure 
disrupts and their content releases in the nucleus.  
In one formulation (Chapter 2), we have used a small molecule (acridine orange) which 
has intrinsic affinity towards DNA80. The molecule is conjugated to the surface of polymersomes 
using the Copper (II)-catalyzed azide-alkyne cycloaddition (“Click” reaction)81. The 
polymersomes encapsulate the drugs gemcitabine and doxorubicin to utilize their synergistic 
effects against pancreatic cancer. The two-drug combination is currently in the clinical trials for a 
variety of advanced and metastatic cancers, including pancreatic ductal adenocarcinoma. 
  
1
7
 
Table 1.3. Pharmacokinetic properties of polymersomal formulations. 
*Terminal phase half life 
Polymersomes 
building blocks 
Drug Dose AUC  Free drug 
AUC  
Drug t1/2 (h) Free drug 
t1/2 (h) 
Animal Ref. 
Polybutadiene 
(PBd)-b- PEG 
NA 0.42 mg/kg of 
polymersomes 
NA NA 24 h NA Male 
 Balb/C mice 
82 
PEG-b-poly(3-
caprolactone 
(PCL) 
Oxymatrine 30 mg/kg of 
drug 
30,602 ± 3982  
ng h/ mL 
16,234 ± 1385 
 ng h /mL 
3.12 ± 0.25* 1.41 ± 
0.57* 
Male Sprague-
Dawley rats 
83 
PEG-PLA Doxorubicin 6 mg/kg of 
drug 
569 
 μg h/mL 
4 
 μg h/mL 
21.9 0.49 Female 
Sprague 
Dawley rats 
77 
PBD-PEO:PEG-
PLA:MAL-
PEG-PLA 
Lactoferrin 
conjugated 
NA 20 mg/kg of 
polymersomes 
219.5 ± 25.6  
mg h /L 
NA 6.49 NA Mice 49 
PBD-PEO:PEG-
PLA:MAL-
PEG-
PLATransferrin 
conjugated  
NA 20 mg/kg of 
polymersomes 
404 ± 49 mg h 
/L 
NA 13.6 NA Mice 49 
PEG-PLA Amphotericin 
B 
1 mg/kg of 
drug 
11,354 
ng h /mL 
NA 73.84* NA Male SD rats 78 
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In the second formulation (Chapter 3), we have used a different strategy to target the cancer 
cell nuclei. We have designed an MMP-7 enzyme responsive, nuclear targeted peptide which only 
gets activated after cleavage by MMP-7 enzyme. MMP-7 enzyme84 is overexpressed in the 
pancreatic cancer tumor microenvironment. Therefore, its overexpression can be used to target the 
tumor microenvironment. Once the peptide on the surface of the polymersomes is cleaved by 
MMP-7, the nuclear localizing signal is activated and transports the vehicle to the cancer cell’s 
nuclei. We encapsulated with curcumin or doxorubicin in the polymersomes and tested their 
simultaneous effect on pancreatic cancer cells. 
The third formulation is cell cytoplasm-targeted polymersomes, designed to target the 
prostate cancer cells. Prostate-specific membrane antigen (PSMA) is overexpressed in prostate 
cancer cells85.  Since the PSMA protein has folate hydrolysis activity86, it can be targeted by the 
folate molecules. We have incorporated folate conjugated-phospholipid PEG derivative in the 
polymersomes structure to target the PSMA protein. To induce apoptosis, we intentionally 
disrupted the calcium homeostasis87 of the cancer cells by suddenly increasing the calcium ion 
concentration in the cytoplasm. High concentration of calcium ions in the presence of folic acid 
salcium phosphate crystal nucleation, which leads to cell death88. The calcium ion encapsulated 
polymersomes are responsive to the reducing environment and release their contents in the prostate 
cancer cell’s cytoplasm.  
This thesis is a paper based thesis and we have planned to publish all the chapters in peer-
reviewed journals (section 2 and 3 are published, and section 4 is submitted). Following paragraphs 
of the introduction are the abstracts for these papers.  
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1.3.1. Acridine Orange Conjugated Polymersomes for Simultaneous Nuclear Delivery of 
Gemcitabine and Doxorubicin to Pancreatic Cancer Cells 
Considering the systemic toxicity of chemotherapeutic agents, there is an urgent need for 
developing new targeted drug delivery systems. Herein, we have developed a new nuclear targeted, 
redox sensitive, drug delivery vehicle to simultaneously deliver the anticancer drugs gemcitabine 
and doxorubicin to the nuclei of pancreatic cancer cells.  We prepared polymeric bilayer vesicles 
(polymersomes), and actively encapsulated the drug combination by the pH gradient method. A 
redox-sensitive polymer (PEG-S-S-PLA) was incorporated to sensitize the formulation to reducing 
agent concentration. Acridine orange (AO) was conjugated to the surface of the polymersome 
imparting nuclear localizing property.  The polymersomes’ toxicity and efficacy were compared 
with those of free drug combination using monolayer and three-dimensional spheroid cultures of 
pancreatic cancer cells.  We observed that the redox sensitive, nuclear-targeted polymersome 
released more than 60% of their encapsulated contents in response to 50 mM glutathione. The 
nanoparticles are non-toxic; however, the drug encapsulated vesicles have significant toxicity.  The 
prepared formulation can increase the drug’s therapeutic index by delivering the drugs directly to 
the cells’ nuclei, one of the key organelles in the cells. This study is likely to initiate research in 
targeted nuclear delivery using other drug formulations in other types of cancers.  
Paper information: Acridine Orange Conjugated Polymersomes for Simultaneous Nuclear 
Delivery of Gemcitabine and Doxorubicin to Pancreatic Cancer Cells. 
(DOI:10.1021/acs.bioconjchem.5b00694, Bioconjugate Chem. 2016, 27, 762−771).7 
https://www.ncbi.nlm.nih.gov/pubmed/26848507 
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1.3.2. Nuclear Localizing Peptide Conjugated, Redox Sensitive Polymersomes for 
Delivering Curcumin and Doxorubicin to Pancreatic Cancer Micro-tumors 
Improving the therapeutic index of anticancer agents is an enormous challenge. Targeting 
decreases the side effects of the therapeutic agents by delivering the drugs to the intended 
destination. Nanocarriers containing the nuclear localizing peptide sequences (NLS) translocate to 
the cell nuclei. In this study, we designed a “masked” NLS peptide which is activated only in the 
presence of overexpressed matrix metalloproteinase-7 (MMP-7) enzyme in the pancreatic cancer 
microenvironment. This peptide is conjugated to the surface of redox responsive polymersomes to 
deliver doxorubicin and curcumin to the pancreatic cancer cell nucleus. We have tested the 
formulation in both two and three-dimensional cultures of pancreatic cancer and normal cells. Our 
studies revealed that the drug encapsulated polymeric vesicles are significantly more toxic towards 
the cancer cells (shrinking the spheroids up to 49%) compared to the normal cells (shrinking the 
spheroids up to 24%). This study can lead to the development of other organelle targeted drug 
delivery systems for various human malignancies.  
Paper information: Nuclear Localizing Peptide-Conjugated, Redox-Sensitive 
Polymersomes for Delivering Curcumin and Doxorubicin to Pancreatic Cancer Microtumors. 
 (DOI: 10.1021/acs.molpharmaceut.7b00014).89 
http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.7b00014 
1.3.3. Targeted Cytoplasmic Calcification: A Drug-Free, Polymersomal Prostate Cancer 
Therapy 
Finding new strategies to treat cancer with lower side effects and increased quality of life 
are important for therapy. Calcium homeostasis dysregulation leads to cell death via several 
mechanisms. We are testing a new strategy to kill cancer cells by intentionally increasing the 
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calcium ion concentration inside the cell cytoplasm. We have targeted prostate cancer cells 
(LNCaP) overexpressing the prostate-specific membrane antigen (PSMA) receptors by 
polymersomes presenting folic acid on the surface. The polymersomes encapsulate a high 
concentration of calcium chloride and release the contents in the cytoplasm in response to the 
increased reducing agent concentration. We used HEK-293 as control cells lacking the PSMA 
receptor on the plasma membrane. In vitro studies in monolayer and three-dimensional spheroids 
revealed the efficient cancer cell killing capabilities (cell viability in monolayer culture: 34% ± 10, 
cell viability in three-dimensional culture: 38 % ± 4) of the formulation. Results of this study can 
be a promising starting point for using less toxic compounds in cancer treatment.  
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2. ACRIDIN ORANGE CONJUGATED POLYMERSOMES FOR SIMULTANEOUS 
NUCLEAR DELIVERY OF GEMCITABINE AND DOXORUBICIN TO PANCREATIC 
CANCER CELLS2 
 
 
 
 
 
 
 
Figure 2.1. Graphical abstract. 
2.1. Introduction 
Pancreatic cancer is one of the leading causes of cancer-related death in the world.90 
Chemotherapeutics have been used as an adjuvant, neoadjuvant, and palliative treatments for the 
disease. For both exocrine pancreatic cancers and neuroendocrine pancreatic tumors (NETs), 
combination chemotherapy is more successful, albeit eliciting severe side effects. While 
gemcitabine is the first line of therapy for pancreatic cancer, doxorubicin and streptozocin are 
usually used to treat NETs.91  The combination of gemcitabine and doxorubicin have shown 
synergistic benefits in different malignancies.92, 93, 94 However, chemotherapeutic side effects 
                                                 
 
2 This section is coauthored by Tayebeh Anajaﬁ, Michael D. Scott, Seungyong You, Xiaoyu Yang, Yongki Choi, 
Steven Y. Qian, and Sanku Mallik. Tayebeh had primary responsibility to conduct all the experiments, analyze the 
data and write the manuscript. Michael had the responsibility to conduct NMR on the polymers. Seungyong imaged 
the polymersomes using AFM. Xiaoyu recorded mass spectrum for the synthesized polymers. Drs. Choi, Qian and 
Mallik verified the data and advised on experimental designs. 
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decrease the patient’s quality of life. As a result, increasing the therapeutic efficacy of conventional 
anti-cancer drugs is one of the important issues in cancer treatment. Targeted drug delivery is an 
attractive solution with many benefits over conventional chemotherapy.  
Mitochondria95, 96 and nucleus,97, 98 the two principal subcellular compartments, have been 
targeted to interrupt cancer cell growth in different malignancies. Mitochondria, known as the 
powerhouse of cells, control all the primary metabolic processes. Consequently, devitalizing this 
organelle can be a strong cell toxicant. However, the impermeable inner membrane limits the 
delivery of therapeutics into this organelle. On the other hand, the nucleus is large compared to the 
mitochondria and controls several vital cellular processes. Therefore, attacking the nucleus is an 
attractive strategy for cell cycle arrest and inducing cell death. The nuclear pore complexes99 in 
the nucleus membrane connect the nucleoplasm to the cytoplasm and regulate the entry and exit 
of small molecules. It is estimated that about 500 -1000 transporters (both active and passive) take 
place through these pores every second.100, 101, 102  
The diameter of the nuclear pores limits the size of the molecules which can be transported 
into the nucleus. Therefore, dilating the nuclear pores is a promising strategy for delivering large 
molecules into the cell nucleus.  For example, the glucocorticoid analog dexamethasone dilates the 
nuclear pores to 110 nm and stimulates the formation of giant pores ( ̴300 nm).103 As a result, this 
steroid is recognized as a therapeutic agent not only to counteract the chemotherapeutic side 
effects, but also to increase the likelihood of nuclear delivery of the drugs (in case of targeted 
therapy).  
Liposomes,104, 105 silica,79 and magnetic nanoparticles106 have been targeted to the cell 
nucleus to release the contents. However, to the best of our knowledge, there is no report of nuclear 
drug delivery using polymersomes. Polymersomes are hollow vesicles prepared from amphiphilic 
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polymers with an aqueous interior (capable of encapsulating hydrophilic compounds), and a 
bilayer membrane (which can incorporate with hydrophobic drugs).3 The presence of the long-
chain polymers renders these vesicles more stable compared to liposomes 3, 13, 14 The hydrophilic 
polymer in the outer layer endows the vesicles with long circulating properties. The size can be 
adjusted ( ̴200 nm) for passive accumulation in tumor site employing the enhanced permeation and 
retention effect.107 Incorporation of biocompatible polymers in polymersome’s structure decreases 
the chance of immune response and systemic toxicity.3, 30  
However, polymersomes’ robust membrane hinders drug release at the target site. 
Consequently, different stimuli have been used to trigger the release of encapsulated contents from 
these vesicles.  These stimuli can be external (light 64 and magnetic field 65), or internal (redox 
potential,19 pH,20, 66, 67 and temperature108). Since the application of internal stimuli is safer, and 
easier, 16 and eukaryote cell nuclei contain a high concentration of reducing agents,109, 110 redox-
sensitive polymersomes have the potential to release rapidly encapsulated drugs the nucleus.   
Herein, we report new redox-sensitive, fluorescent polymersomes, encapsulating the 
anticancer drugs gemcitabine and doxorubicin.  We conjugated acridine orange (AO, which has 
an intrinsic affinity toward DNA due to intercalation) on the surface of the polymersomes (Figure 
2.2) for active targeting to the cell nuclei.80, 111, 112 AO  has been used as imaging agents for in vivo 
models113 and as a therapeutic agent in human sarcomas.114 The nuclear localization of the vesicles 
was confirmed by fluorescent microscopy. We demonstrated the efficacy of the nano-vesicles 
employing both conventional two-dimensional monolayer culture and three-dimensional spheroids 
of pancreatic cancer cells. We note that the nuclear localization of AO is not selective for the 
cancer cells.  However, the size of the polymersomes and the presence of the PEG layer will allow  
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them to accumulate selectively in the tumors due to the Enhanced Permeation and Retention (EPR) 
effect.115, 116 
 
Figure 2.2. Schematic representation of acridine orange conjugated to the surface of polymersomes 
encapsulating the anticancer drugs doxorubicin and gemcitabine.  
2.2. Results and Discussion 
2.2.1. Polymer Synthesis, Polymersome Preparation, and Characterization 
The ratio of hydrophilic to hydrophobic parts of a copolymer (f value) has an important 
role in polymersome formation.17, 18 The block co-polymers we have used in this study (Figure 
2.1) have f values of about 25%. The block copolymers were synthesized using ring-opening 
polymerization) (Appendix A), and their average molecular weights were measured by 1H NMR 
spectroscopy. To impart redox-sensitive property, we have prepared the disulfide containing 
polymer (Figure 2.3 A). In addition, to conjugate the nuclear localizing group (alkyne conjugated 
acridine orange, Figure 2.4) to the surface of the polymersomes, we used azide-alkyne 
cycloaddition reaction81 (Scheme 2.1). Hence, azide-terminated polymers were prepared (Figure 
2.3 B) and incorporated into the polymersomes. The ratio of these polymers was optimized based 
on the release of encapsulated calcein from the vesicles. We have removed any free (un-
conjugated) AO from the polymersomes employing a Sephadex gel filtration column (Materials 
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and Methods). Hence, we do not anticipate any significant amount of free AO in the 
polymersomes. 
 
Figure 2.3. The structure of the synthesized polymers used in preparing the polymersomes. A: PEG 
(1900)-S-S-PLA (6100), B: N3-PEG (2000)-PLA (6000).  A small amount of the fluorescent 
lissamine rhodamine lipid (C) was incorporated in the polymersomes for ease of visualization. 
 
Figure 2.4. Alkyne conjugated acridine orange moiety. 
To confirm the presence of the AO on the surface of the polymersomes, we monitored the 
fluorescence emission spectra (excitation: 450 nm) of polymersomes before and after the “Click” 
reaction (Figure 2.5 C). We chose the excitation at 450 nm since lissamine rhodamine does not 
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have significant absorption at this wavelength (Figure 2.5 A). The spectral overlap between the 
emission from acridine orange (500 nm – 600 nm, Figure 2.5 B) and absorption of lissamine 
rhodamine (Figure 2.5 A) indicated the possibility of energy transfer between these two dyes when 
present on the surface of the polymersomes. The clear difference between the emission intensity 
of the lissamine rhodamine at 575 nm before and after AO conjugation (Figure 2.5 C, blue and 
green traces) is likely due to the energy transfer from excited state AO to the ground state of 
lissamine rhodamine.  The energy transfer precluded us from determining the concentration of 
conjugated AO using fluorescence spectroscopy.  Before the release experiments, we removed any 
free AO from the polymersomes by gel filtration (Materials and Methods). From the initial 
concentrations of the polymersome components and the dilution factor for gel filtration, we 
estimated that the concentration of the lissamine rhodamine to be nearly the same before and after 
the AO conjugation reaction.  We used 40 mol% of azide containing polymer, and considering 
about 60% of this polymer will be exposed to the surface, we estimate that 0.03 µmol of the AO 
moiety has been conjugated to the surface of the polymersomes.  
 
Scheme 2.1. Functionalization of the polymersomes using the Cu2+ catalyzed [2+3]-cycloaddition 
reaction.   
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Figure 2.5. Characterization of acridine orange (AO) conjugation to the polymersomes by 
fluorescence spectroscopy. (A) Absorption spectra of lissamine rhodamine lipid (red trace) and 
AO (black trace). (B) Emission spectra for lissamine rhodamine lipid in chloroform (red trace), 
and AO in DMSO (black trace) (excitation: 450 nm). (C) Emission spectra (excitation: 450 nm) 
of the polymersomes before (blue trace) and after (green trace) the “Click” reaction.   
Polymersomes were prepared using the solvent exchange method,3 and their morphology 
were confirmed by transmission electron microscopy (TEM, Figure 2.6) and atomic force 
microscopy (AFM, Figure 2.6). Size distribution and polydispersity index of the polymersomes 
were determined by light scattering method (Figure 2.9). To improve the tumor accumulation by 
the enhanced permeation and retention effect,107 the prepared polymersomes possess a 
hydrodynamic diameter of 170 + 4nm. We observed that the size of the polymersomes increased 
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slightly after conjugation of acridine orange (Table 2.1). We noted a similar size increase after 
drug encapsulation, possibly due to drug precipitation117 inside the polymersomes’ aqueous core 
(Table 2.1). 
 
 
 
 
 
 
Figure 2.6. Transmission electron microscopic (TEM) images of polymersomes. The scale bar in 
A is 20 nm, and in B is 100 nm. 
2.2.2. Demonstration of Redox-Triggered Contents Release from the Polymersomes 
The tripeptide glutathione (γ-glutamyl-cysteinyl-glycine, GSH) is one of the major 
components for maintaining redox homeostasis in the cytoplasm and organelles such as nucleus 
and mitochondria.118 GSH concentration is higher in the cancer cells compared to the healthy 
counterparts.  In addition, the cell nucleus contains higher amounts of this tripeptide compared to 
the cytosol.118 We have used these concentration differences to trigger drug release from the 
polymersomes inside the nuclei of PANC-1 cells. Specifically, we have studied the release of 
encapsulated calcein in the presence of 10 mM (mimicking cytosol) and 50 mM (mimicking cell 
nucleus) GSH.  We observed that 10 mM GSH released about 15% of the encapsulated calcein 
from the polymersomes during 40 minutes. However, in the presence of 50 mM GSH, 55% of 
calcein was rapidly released from the vesicles (Figure 2.9). The lack of complete contents release 
possibly indicates that the vesicles are undergoing morphological changes in the presence of 50 
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mM GSH, rather than a complete loss of structure.  Our atomic force microscopic studies 
corroborate this hypothesis (Figure 2.7, Panel I). 
 
Figure 2.7. Atomic Force Microscopy (AFM) images of polymersomes. (A-C) AO-polymersomes 
before glutathione treatment. (D-F) AO-polymersomes treated with 10 mM glutathione. (G-I) AO-
polymersomes treated with 50 mM glutathione. (J) Height profile overlay of the polymersomes 
(green trace: no glutathione), blue (10 mM glutathione), and red trace (50 mM glutathione). The 
scale bar in (A) is 2 µm. 
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Table 2.1. Hydrodynamic diameters of the polymersomes before and after AO conjugation, and 
after drug encapsulation.  
 
Polymersomes Average hydrodynamic 
diameter (nm) 
Polydispersity Index (PDI) 
Polymersomes 129.1 ± 6.6 0.2 ± 0.02 
AO-polymersomes 170.3 ± 4.1 0.2 ± 0.01 
Polymersomes encapsulating 
doxorubicin and gemcitabine 
242.1 ± 6.6 0.3 ± 0.02 
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Figure 2.8. Size distribution of the polymersomes as determined by dynamic light scattering. (A) 
Polymersomes before AO conjugation, (B) AO-conjugated polymersomes, and (C) AO-
polymersomes encapsulating gemcitabine and doxorubicin. 
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Figure 2.9. Release profile of the polymersomes. Calcein release was monitored for 40 minutes 
after adding 10 mM GSH to the polymersomes. The concentration of GSH was then increased to 
50 mM, and the release was monitored for another 40 minutes.  The plot is the average of three 
release profiles. 
2.2.3. Effect of Redox Potential Changes on Polymersome Structure 
We decided to study the GSH-mediated changes in the polymersome structure employing 
atomic force microscopy (AFM).  We observed that treating the polymersomes with 10 mM GSH 
did not have a significant effect on their spherical shape (Figure 6B). However, incubation of the 
vesicles with 50 mM GSH destroyed the spherical shape (Figure 6C).  
2.2.4. Gemcitabine and Doxorubicin Encapsulation in the Polymersomes 
For the cellular studies, we encapsulated gemcitabine and doxorubicin in the 
polymersomes using the active pH gradient method (described in the Material and Methods). The 
encapsulation efficiency, determined employing a dual-wavelength method developed in our 
laboratory,19 was found to be 76% for gemcitabine and 22% for doxorubicin. These two anticancer 
drugs affect different biochemical pathways to kill cancer cells, and the combination shows 
synergistic benefits.119  
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2.2.5. Demonstration of Nuclear Localization and Polymersomes’ Efficacy Using 
Monolayer Cell Culture 
After optimizing the release from the polymersomes, we proceeded to demonstrate nuclear 
localization of the vesicles employing the conventional, monolayer culture of the PANC-1 cells. 
To facilitate nuclear localization, we treated the cells with dexamethasone (80 µM) before adding 
the polymersomes. Dexamethasone is reported to dilate the nuclear pores.103  After incubation and 
washing, we imaged the PANC-1 cells in a confocal fluorescence microscope (Figure 2.10).  We 
observed that the AO-polymersomes accumulated in the cell nuclei more efficiently (Figure 2.10, 
Column 2, AO-polymersomes loaded with drugs) compared to the control vesicles lacking the AO 
moiety (Figure 2.10, Column 1, Polymersomes loaded with drugs) or the free drugs (Figure 2.10, 
Column 3, Free Dox).  The efficiency of AO-polymersomes is likely due to the intercalation of the 
AO group to nuclear DNA106 in the PANC-1 cells. In a separate experiment, we incubated the 
PANC-1 cells with AO-polymersomes without dexamethasone pre-treatment. We noticed a 
decrease in nuclear localization of the polymersomes, indicating the effect of dexamethasone in 
enhancing nuclear delivery (Figure A1).   
To evaluate the efficacy of the drug encapsulated polymersomes, we performed Alamar 
Blue assay using the monolayer cultures of PANC-1 cells (Figure 2.11). We observed that the AO-
polymersomes (without any drugs) were non-toxic to the cells (Figure 2.11, green column).  The 
combination of gemcitabine and doxorubicin was toxic to the cells, with a cell viability of 31% 
(Figure 2.11, blue column).  Also, the AO-polymersomes encapsulating the two drugs decreased 
the cell viability to 36% (Figure 2.11, red column). 
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2.2.6. Demonstration of Polymersomes’ Efficacy Using Three-dimensional, Spheroid 
Cultures 
The multicellular spheroids are better mimics of tumors due to the cell-cell interactions and 
the three-dimensional shape. Among the reported approaches to growing cancer cell spheroids,120, 
121, 122 we selected the agar micromolds.123 In this approach, 96 similar size spheroids are obtained. 
We monitored the growth of the PANC-1 cell spheroids (Figure 2.12) employing a confocal 
microscope.  After 8 days of culture, we observed a hypoxic core and a surrounding proliferating 
layer of the cells in the spheroids (Figure 2.12, Panel D). Furthermore, to better understand the 
spheroids shapes, we have imaged the 8-day old spheroids at multiple focal planes (Appendix A). 
To determine cell viability, we treated the 5 day old spheroids with the polymersomes. After 72 
hours, the spheroids were dislodged, trypsinized to prepare a homogenous single cell suspension, 
and the cell viability assays were performed (Figure 2.11). We observed that the drug encapsulated 
AO-polymersomes reduced the cell viability to 30% (Figure 2.11, red column). Comparison of 
Figures 10 A and 10 B also demonstrates that the polymersomes’ effectiveness is not diminished 
in cancer cell spheroids compared to the monolayer cultures.  
To further demonstrate the efficiency of the drug encapsulated AO-polymersomes, we 
treated the 8 day old spheroids with the polymersomes, washed, and monitored their growth for 
another 6 days (Figure 2.13). We observed that the untreated spheroids nearly doubled in size in 
11 days (Figure 2.13, green circles).  The free drug combination decreased the growth to 29% 
(Figure 2.13, pink inverted triangles).   However, the drug encapsulated, AO-polymersomes shrank 
the PANC-1 spheroids to 3% after 14 days, rendering them nearly same in size as the 3-day old 
cultures (Figure 2.13, red circles). 
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Figure 2.10. Confocal fluorescence microscopic images of nuclear localization of polymersomes 
in PANC-1 cells. (A) Bright field microscopy image, (B) Hoechst stained nuclei of the cells (DAPI 
filter), (C) images recorded with FITC filter (the green color is showing the AO location), (D) 
images recorded using TRITC filter (the red color is showing the presence of doxorubicin or 
lissamine rhodamine), and (E) overlayed images (scale bars: 200 µm). 
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Figure 2.11. Viability analysis of PANC-1 cells. The cells were treated with AO-polymersomes 
(green column), drug encapsulated AO-polymersomes (red column) or free drug combination 
doxorubicin-gemcitabine (blue column) in monolayer culture (A), and in 3D spheroids (B). (*P < 
0.05, **P < 0.01, N = 4) 
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Figure 2.12. Confocal microscopic image of 3D spheroids of PANC-1 cells. (A) Spheroids after 2 
days, (B) 4 days, (C) 5 days, and (D) 8 days. The presence of the hypoxic core is apparent in the 
Panels C and D. The proliferating layer of the cells surround the hypoxic core (Scale bars: 50 µm).  
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Figure 2.13. Growth curves for the PANC-1 cell spheroids treated with polymersomes. The 8 days 
old spheroids were treated with drug encapsulated non-targeted polymersomes (black squares), 
drug encapsulated targeted polymersomes (red circles), targeted polymersomes without any drugs 
(blue triangles), and the free drug combination (pink inverted triangles). The Control group was 
treated with HBSS buffer (green circles). The lines connecting the observed data points are 
depicted in the figure (N = 3). 
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2.3. Conclusions 
We prepared polymersomes incorporating the reduction-sensitive copolymer and another 
amphiphilic copolymer with the azide group at the hydrophilic terminus. The cell nucleus targeting 
group acridine orange was conjugated to the polymersomes employing the [2+3]-cycloaddition 
reaction.  We demonstrated that the resultant polymersomes were stable in cytosolic concentration 
of glutathione. However, the polymeric vesicles are unstable in a higher concentration of the 
reducing agent, as observed in the cell nucleus.  We have successfully encapsulated the anticancer 
drugs gemcitabine and doxorubicin in the acridine orange-conjugated polymersomes. We have 
demonstrated that acridine orange facilitates the accumulation of the polymeric vesicles in the 
nuclei of pancreatic cancer cells. Although the polymeric vesicles are non-toxic, we observed that 
the drug encapsulated polymersomes significantly reduced the viability of pancreatic cancer cells 
in monolayer as well as in three-dimensional spheroid cultures, and decreased the volume of the 
pancreatic cancer cell spheroids.   
2.4. Materials and Methods 
2.4.1. Synthesis and Characterization of Polymers 
Two different polymers have been synthesized in our laboratory to form the polymersomes. 
PEG (1900)-S-S-PLA (6100) polymer (Figure 2.3A) was synthesized as previously 19. The other 
polymer, N3-PEG (2000)-PLA (6000), Figure 2.3B, with an azide moiety to facilitate the 
conjugation reaction, was synthesized and characterized by NMR spectroscopy.  
2.4.2. Synthesis and Characterization of Alkyne-conjugated Acridine Orange 
The alkyne conjugated acridine orange (Figure 2.4) was synthesized and characterized by 
NMR and ESI mass spectroscopy as described in Figure A2.  
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2.4.3. Polymersome Preparation 
To prepare the polymersomes with controlled size and narrow size distribution, we used 
the solvent exchange method 3. We dissolved the polymers in tetrahydrofuran (THF), and added 
dropwise to an aqueous buffer under stirring. The method is described in the following paragraph.  
2.4.4. Preparation of Calcein Encapsulated Polymersomes 
The synthesized polymers (PEG-S-S-PLA and N3-PEG-PLA, Figure 2.3) were solubilized 
in THF in molar ratio of 60:40 respectively. A calcein solution (10 µM) was prepared in HEPES 
buffer (10 mM, pH 7.4). The polymer solution was added dropwise to the calcein solution while 
stirring to prepare a 1 mg/mL polymersome suspension. Subsequently, THF was evaporated by 
passing air through the solution, and the polymersomes were subjected to bath sonication 
(Aquasonic, 250D, power level 9) for an hour at room temperature.  
2.4.5. Acridine Orange (AO) Conjugation and Characterization 
To conjugate the acridine orange moiety to the surface of polymersomes (Figure 2.2), 
copper catalyzed azide-alkyne cycloaddition (“click” reaction) was used. To 1 mL of polymersome 
solution (1 mg/mL), the alkyne conjugated acridine orange (1:2 molar ratio of azide: alkyne), Cu2+ 
complex (50 μL of 0.053 M aqueous solution, prepared by mixing aqueous solution of CuCl2, 0.53 
mmol, and N,N,N′,N′,N′′-pentamethyldiethylenetriamine, PMDTA, 2.1 mmol), and sodium 
ascorbate (50 μL of 27 mg/mL aqueous solution, 1.4 μmol) was added 124, 125. The resultant mixture 
was kept overnight at room temperature in dark while stirring (Scheme 2.1). The conjugated 
polymersomes were separated from the reaction mixture by passing the solution through a 
Sephadex G-100 (GE Healthcare) size exclusion column. To verify the presence of AO on the 
surface of polymersomes, we compared the fluorescence emission spectra (excitation: 450 nm) of 
the polymersomes before and after the “Click” reaction (Figure 2.5). 
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2.4.6. Preparation of Doxorubicin and Gemcitabine Encapsulated Polymersomes 
We prepared the polymersomes via solvent exchange and used the pH gradient method 19 
for active drug encapsulation.  PEG-S-S-PLA and N3-PEG-PLA polymers along with 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl, ammonium salt) (60:35:5 
molar ratio) were used for preparing the polymersomes. The polymersomes were prepared in 
citrate buffer (pH 4.0, 20 mM), and before drug encapsulation, the pH of the external solution was 
increased to 7.0 by the addition of aqueous sodium bicarbonate. Subsequently, a solution 
containing doxorubicin hydrochloride (Bridge Bioservices) and gemcitabine (Matrix Scientific) 
with 1:1 ratio (0.2 mg/mL in water each) was added to the prepared polymersomes. The resultant 
mixture was heated for 10 minutes at 60 °C and then kept at room temperature for 3 hours. The 
mixture was passed through a Sephadex G-100 (GE Healthcare) size exclusion column to separate 
the un-encapsulated drugs from the polymersomes. The drug loading efficacy was calculated by 
comparing absorbance spectra of polymersomes before and after size exclusion chromatography 
(Figure A3).  
2.4.7. Determination of Doxorubicin and Gemcitabine Encapsulation Efficiency 
The drug encapsulation efficacy was calculated based on a previously established protocol 
in our laboratory 19. Briefly, the concentration of doxorubicin was calculated by monitoring the 
polymersomes’ absorbance at 483 nm. Doxorubicin has equal absorbance at 483 nm and 279 nm, 
and gemcitabine has the absorbance maximum at 270 nm. We estimated the gemcitabine 
concentration by subtracting the absorbance of polymersomes at 483 nm from the absorbance at 
270 nm, and using a calibration curve for gemcitabine.  
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2.4.8. Size-distribution Analysis 
Size distribution analysis of the polymersomes (1 mg/mL) was performed using a dynamic 
light scattering instrument (NanoZS 90, Malvern Instruments). Measurements were conducted at 
a scattering angle of 90° in disposable polystyrene cuvettes. Each sample was equilibrated for 30 
seconds, and 10 measurements per sample were recorded (repeated 4 times). 
2.4.9. Atomic Force Microscopy (AFM) 
An atomic force microscope (AFM) was used to image the polymersomes on a mica 
surface. AFM measurements were carried out in non-contact mode at a scanning rate of 0.7 Hz 
and a resonance frequency of 145 kHz using an NT-MDT NTEGRA (NT-MDT America). The 
scanning areas were 5 × 5 or 20 × 20 m at the resolution of 512 or 1024 points per line, 
respectively. The images were flattened by a first order line correction and a first order plane 
subtraction to compensate a sample tilt. The polymersome solution was dropped on top of a freshly 
cleaved mica surface. The dropped solution was left at room temperature for 10 minutes for non-
specific attachments of the polymersomes on the mica surface. The remaining solution was rinsed 
away with water and dried extensively with an air blow gun, and then the images were recorded. 
For imaging the polymersomes after GSH treatment, the same procedure was followed.  
2.4.10. Transmission Electron Microscopy (TEM) 
Polymersomes prepared in HEPES buffer (1 mg/mL, pH: 7.4), were subjected to negative 
staining for imaging using a Transmission Electron Microscope (JEOL JEM 2000, accelerating 
voltage set to 100 kV). The polymersome solution (10 µL) was dropped on a 300-mesh, Formvar-
coated copper grid (coated with 0.01% poly-L-lysine). After one minute, the extra sample was 
wicked using a filter paper and stained using 1% phosphotungstic acid for 1.5 minutes. 
Subsequently, excess dye was blotted using filter paper, and dried samples were imaged. 
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2.4.11. Redox-triggered Release from the Polymersomes 
We used the calcein-encapsulated polymersomes to demonstrate contents release in the 
presence of glutathione (GSH).  The un-encapsulated calcein was quenched by adding 10 mM 
CoCl2 solution to the buffer. The release of the encapsulated calcein (10 µM) was monitored by 
fluorescence spectroscopy in a 96-well plate (Spectramax M5, Molecular Devices; excitation: 495 
nm, emission: 515 nm) over 40 minutes after treating the polymersomes (20 µL, 1mg/mL) with 10 
mM GSH. Subsequently, 40 mM GSH was added to the solution and release profile was monitored 
for another 40 minutes (the experiment was repeated 3 times). Subsequently, the percent release 
of calcein was calculated and plotted. 
2.4.12. Cell Culture 
PANC-1 cells (pancreatic ductal carcinoma cell line, purchased from ATTC), was cultured 
in DMEM medium supplemented with 1% (v/v) antibiotic-antimycotic solution (containing 
penicillin, streptomycin, amphotericin B), and 10% fetal bovine serum in 75 cm2 tissue culture 
flasks incubated at 37 °C in humidified atmosphere and 5% CO2. 
2.4.13. Nuclear-targeting Studies 
The PANC-1 cells, when 90% confluent, were trypsinized and subcultured in a sterile, 96-
well tissue culture plate. Once confluent, the cells were divided into three different treatment 
groups, including plain polymersomes (without AO on the surface), AO-polymersomes, and a 
negative control group without any treatment. Polymersome concentration was 0.02 mg/mL, and 
we repeated each experiment 3 times. After treatment, the cell nuclei were stained using 
HOESCHT 33342 dye (Enzo Life Sciences) according to the manufacturer’s protocol. 
Subsequently, excess polymersomes and dye were washed out gently from the wells using HBSS 
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(HyClone, ThermoScientific), and cells were imaged using 20X objective of an Olympus IX81 
motorized inverted fluorescent microscope. 
2.4.14. Cell Viability Studies (Monolayer Cell Culture) 
Alamar Blue cell viability assay was used to determine the cytotoxicity of the formulations. 
Five thousand cells were seeded in a 96-well, clear bottom plate and incubated until 70% confluent. 
The confluent wells were pretreated with dexamethasone and then treated with AO-polymersomes 
encapsulating HEPES buffer (10 mM), AO-polymersomes encapsulating gemcitabine and 
doxorubicin, and gemcitabine-doxorubicin combination (4 repeats per treatment). The treated cells 
were incubated for 72 hours at 37 °C. Subsequently, the cells were washed using HBSS solution, 
fresh media was added to the wells, and Alamar Blue assay was conducted to measure the viability 
of cells by following the manufacture’s (Life Technologies) protocol. The fluorescence intensity 
of the reduced form of resazurin (resorufin) was monitored (excitation at 560 nm and emission at 
590 nm) using a spectrofluorimeter, and cell viability were compared to the control wells (no 
treatment). 
2.4.15. Three Dimensional (3D) Spheroid Cell Culture 
To form the PANC-1 cell spheroids, 3D Petri Dish® (Microtissues, natural 3D) were used. 
The agar molds capable of forming 96 similar spheroids were equilibrated with DMEM media 
overnight at 37 °C. Subsequently, the PANC-1 cells were seeded in the agar plates following the 
manufacturer’s protocol and were incubated for 3 days to form spheroids. The media surrounding 
the agar plates were replaced with fresh media as needed. The spheroids were imaged at different 
time points using a confocal microscope (Olympus Fluoview) and finally imaged at different focal 
planes.  
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2.4.16. Cell Viability Studies (3D Spheroid Culture) 
The 5 days old spheroids were used for cell viability studies using Alamar Blue. Each plate 
containing 96 spheroids were pretreated with dexamethasone (8 µM), and then treated using AO-
polymersomes (0.02 mg/mL) encapsulating HEPES (10 mM), gemcitabine and doxorubicin 
loaded polymersomes, and gemcitabine-doxorubicin combination for 72 hours. Then, the media 
were replaced with fresh media and the spheroids were dislodged from the agar plate by 
extensively triturating. The Spheroids were trypsinized to make a single cell suspension, and the 
cells were seeded in a 96 well plate (each 4 repeats). The cells were incubated for one doubling 
time and treated with fresh media-Alamar Blue mixture. The fluorescence of the reduced form of 
resazurin was monitored as described previously. 
In a separate experiment, to check the ability of the polymersomes to shrink the spheroids, 
we treated the 7 day old spheroids with different formulations: AO-polymersomes (0.02 mg/mL) 
encapsulating HEPES (10 mM), gemcitabine and doxorubicin loaded polymersomes targeted with 
AO, gemcitabine and doxorubicin loaded, non-targeted polymersomes, and gemcitabine-
doxorubicin combination for 72 hours. The growth of the spheroids was monitored for 14 days to 
obtain a growth curve. Spheroid’s images were analyzed by an image processing software 
(cellSens Standard 1.6, Olympus Corporation). 
 
 
 
 
 
 
 44 
 
3. NUCLEAR LOCALIZING PEPTIDDE CONJUGATED, REDOX SENSITIVE 
POLYMERSOMES FOR DELIVERING CURCUMIN AND DOXORUBICIN TO 
PANCREATIC CANCER MICRO-TUMORS3 
 
 
 
 
 
 
 
 
Figure 3.1. Graphical abstract. 
3.1. Introduction 
Chemotherapeutic agents are commonly used in treating most of the cancers. Due to the 
non-specific distribution of the drugs, patients suffer from significant side effects of the 
chemotherapy. The development of chemo-resistance is another limiting factor in treating 
cancer126. Considering the limited number of targeted drug delivery systems in clinical 
development127, there is an urgent need for efficient carriers which release the drugs only at the 
                                                 
 
3 This section is coauthored by Tayebeh Anajaﬁ, Junru Yu, Abbas Sedigh, Manas K. Haldar, Wallace W. Muhonen, 
Seth Oberlander, Heather Wasness, Jamie Froberg, MD Shahjahan Molla, Kalpana S. Katti, Yongki Choi, John B. 
Shabb, D. K. Srivastava, and Sanku Mallik. Tayebeh had primary responsibility to conduct all the experiments, 
analyze the data in and write the manuscript. Junru and Abbas synthesized recombinant MMPs. Manas had primary 
synthetized the polymers. Wallace recorded MALDI mass spectrum for synthesized peptide. Seth and Heather 
assisted in peptide purification. Jamie imaged the polymersomes using AFM. MD Shahjahan recorded the IR 
spectra. Drs. Katti, Choi,Shabb, Srivastava and Mallik verified the data and advised on experimental designs. 
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target site. After reaching the intended site, often the drug molecules need to traverse through 
cellular barriers and reach the particular cell compartment to exert the biochemical effects.  As a 
result, only a small percentage of the active drug reaches the intracellular target organelle54. 
Therefore, delivering the drugs in the cell organelles is a more promising strategy to increase the 
chemotherapeutic efficacy. The cell nucleus, the largest organelle housing the genetic materials 
and the transcription machinery, is an attractive target for drug delivery79.   
Several nuclear localizing peptides [e.g., simian virus 40 (SV40) T-antigen derived 
peptide54, 128, TAT peptide129, and transportan53] are widely used as targeting agents for drug and 
gene delivery.  For example, the Lima group have used an SV40 T-antigen derived peptide to 
develop a nonviral delivery system for high molecular weight cargos130. The peptide rapidly enters 
the cell nucleus in a dose-dependent manner131.   However, the nuclear localization peptides are 
non-selective and cannot distinguish the malignant cells from the healthy counterparts. 
Matrix metalloproteinase (MMPs) enzymes are the largest group of endopeptidases with 
an important role in extracellular matrix remodeling132 in physiological (e.g. tissue remodeling133) 
and pathological conditions (e.g. cancer134 and heart diseases135). Among MMPs, the matrix 
metalloproteinase-7 (MMP-7) isozyme is overexpressed in the tumor site in several 
malignancies84, 136 including pancreatic cancer. Hence, designing a nuclear localizing peptide 
which gets activated at the tumor site, in response to MMP-7 overexpression, is a promising 
strategy for targeting the tumor microenvironment.   
Our overall goal is to prepare smart delivery vehicles to target the tumor cell nuclei and 
decrease the side effects of chemotherapeutic drugs. Herein, we have designed nanocarriers 
(polymersomes3) that accumulate at the tumor site by the Enhanced Permeation and Retention 
(EPR) effect115 and release the drugs (doxorubicin/curcumin) in response to the local biochemical 
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abnormalities137. We have prepared MMP-7 isozyme responsive, nuclear localizing, redox-
sensitive polymersomes by conjugating the vesicles to a protected nuclear localization peptide137. 
We have shown that MMP-7 hydrolyzes the masking peptide and exposes the nuclear localization 
sequence (NLS) on the polymersome surface, facilitating the cellular internalization preferentially 
in the cancer cells, and subsequent nuclear transport of the vesicles.  The high reducing agent 
concentration in the nucleus destabilizes the vesicles and release the encapsulated content (Figure 
3.2).  The polymersome formulation is tested in vitro using monolayer and three-dimensional 
spheroid cultures of human pancreatic cancer cells. Results of this study have the potential to 
contribute to the design of polymersome formulations which are more efficient than the current 
triggered release vehicles against various malignancies, and especially pancreatic cancer.  
3.2. Results and Discussion 
3.2.1. Polymer Synthesis and Characterization 
To impart redox-sensitive properties to the polymersomes, we have synthesized a 
copolymer with a disulfide bond (Figure 3.3A) linking the hydrophilic and hydrophobic blocks. 
To conjugate the “masked” NLS peptide to the surface of polymersomes, we have used the azide-
alkyne cycloaddition reaction138. Hence, we have also synthesized an azide terminated PEG-PLA 
copolymer (Figure 3.3B).  Polyethylene glycol (PEG) was used as the hydrophilic block for both 
polymers to increase the circulation times of the resultant polymersomes139. The ratio of the 
hydrophilic part to the total mass of a copolymer (f value) is important for polymersome formation, 
with an f value between 25-40% being optimal140. Therefore, we have synthesized the polymers 
such that the f values are close to this range (PEG-S-S-PLA, f: 24%, N3-PEG-PLA, f: 25%). 
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3.2.2. Peptide Design, Synthesis, and Purification 
We chose the SV40 nuclear localizing signal peptide (PKKKRKV)141 as the organelle (cell 
nucleus) targeting moiety. However, the NLS peptide is nonspecific in the electrostatic interactions 
with the cell membrane142. Hence, we have used a negatively-charged masking domain (EEEE) to 
neutralize the positive charges of the NLS peptide143. The matrix metalloproteinase isozyme 
MMP-7 is overexpressed in the pancreatic cancer microenvironment84. We have linked the NLS 
peptide and the masking domain via a short peptide containing the MMP-7 cleavage site (GPMG-
IAGQ)144 (Figure 3.4). Considering the low MMP-7 enzyme concentration in the blood145, we 
anticipate that the resultant vesicles would be stable in the circulation with the negative charges 
masking the NLS peptide. However, as the polymersomes accumulate at the tumor site by the EPR 
effect, MMP-7 would cleave the substrate peptide, separating the NLS from the masking domain 
(illustrated in Figure 3.2). Hence, conjugating the peptide to the surface of the vesicles would 
confer tumor and cellular organelle (nucleus) targeting properties to the polymersomes. To attach 
the peptide to the surface of the polymersomes, we conjugated hexynoic acid to the peptide’s N-
terminus. 
We synthesized the peptide using a microwave-assisted, solid phase synthesizer, purified 
by RP-HPLC, and characterized by mass spectrometry (Figure B1).  We anticipated that the 
electrostatic interactions between the NLS and masking domains of the synthesized peptide would 
be affected by temperature. Temperature-dependent CD spectroscopy showed an isosbestic point 
– indicating the lack of any intermediate during the melting process (Figure 3.5).   
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Figure 3.2. Schematic representation of the study design. (A) Peptide design and delivery vehicle 
representation. (B) Enzymatic cleavage of the peptide by MMP-7 (activation of the NLS) in the 
proximity of tumor, and nuclear localization of the nanovesicles. 
 
Figure 3.3. The structures of the synthesized amphiphilic block copolymers.  
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Figure 3.4. Peptide structure and the Click reaction. (A) Synthesized peptide sequence. 
Methionine in position P2 is labeled by red color. (B) Conjugation of the peptide to the 
polymersome surface (N3-PEG-PLA) employing the Cu2+ catalyzed [2+3]-cycloaddition reaction 
(PMDTA: N, N, N′, N′, N′′-pentamethyldiethylenetriamine). 
3.2.3. Peptide Cleavage Studies 
Previous studies indicated that the substitution of methionine in the P2 position of the 
substrate peptide provides selectivity for the MMP-7 isozyme over MMP-9144. We tested the 
selectivity of MMP-1, -7, and -9 to hydrolyze the synthesized peptide (shown in Figure 3.3). In 
this endeavor, we incubated the pure peptide with recombinant human MMP-1, -7, and -9 
separately at room temperature for an hour, and recorded the CD spectra (Figure 3.6). We 
subtracted the CD spectra of the MMP isozymes as the “blank.”  We observed that only MMP-7 
significantly changed the CD spectrum of the peptide, indicating selective hydrolysis.  
 
 50 
 
Figure 3.5. Temperature-dependent (5 – 50 oC) CD spectra of the purified peptide. The peaks at 
218 nm and 197 nm decreased with increase in temperature (indicated by the arrows). The 
isosbestic point suggests the lack of any intermediate during the melting process of the peptide. 
 
3.2.4. Polymersome Preparation and Characterization 
We prepared the polymersomes by solvent exchange (Materials and Methods) using our 
previously-optimized ratio of the PEG-S-S-PLA and N3-PEG-PLA (60:40) for the reduction-
triggered release of encapsulated contents7. The hydrodynamic diameter and size of the 
polymersomes were determined using dynamic light scattering (DLS, Figure 3.7A) and 
transmission electron microscopy (TEM, Figure 3.7B). DLS indicated that the average diameter 
of the vesicles was 143 + 3 nm with a polydispersity index of 0.2 + 0.02. 
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Figure 3.6. Selective hydrolysis of the synthesized peptide by MMP-7. The CD spectrum of the 
peptide after 1 h incubation with 2 µM of MMP-9 (A), MMP-1 (B), or MMP-7 (C). The CD 
spectra of the MMP isozymes were used as the “blank.” Black trace: pure peptide before 
cleavage, red trace: peptide after incubation with the enzymes. 
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Figure 3.7. Characterization of the polymersomes. (A) Size distribution of the polymersomes by 
dynamic light scattering (N = 5). (B) TEM images of the polymersomes (scale bar: 200 nm). 
B 
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3.2.5. Conjugation of the “Masked” NLS Peptide on the Polymersomes (“Click” Reaction) 
We conjugated the NLS–MMP-7 substrate–EEEE peptide (shown in Figure 3.4A) to the surface 
of the polymersomes applying the azide-alkyne cycloaddition reaction (schematically shown in 
Figure 3.4B).  After removing any unconjugated peptide by extensive dialysis, we recorded the 
FT-IR spectrum of the vesicles (Figure 3.8). The 1, 2, 3-triazole ring has a characteristic 
absorbance near 1110-1050 cm-1 146. The band at 1108 cm-1 can be assigned to that structure. The 
band at 1419 cm-1 is likely due to the N=N stretching or triazole ring skeletal vibration. The band 
at 1351 cm-1 and 1214 cm-1 likely indicate the C-N stretching147. Analyzing the spectra, we 
concluded that the reaction between polymer and peptide has occurred, generating the cyclic 1, 2, 
3-triazole. The band at 720 cm-1, present only in the peptide spectra (Figure 3.8A), is possibly due 
to the C-H deformation from the -C≡CH. A characteristic absorbance is observed in the region 
2170-2080 cm-1 for organic azides148, 149. In the spectra of the polymer N3-PEG-PLA, the band at 
2104 cm-1 could be assigned for N=N=N asymmetric stretching vibration (Figure 3.8B).  We note 
that this band is not observed in the IR spectra for the peptide conjugated polymersomes (Figure 
3.8B), indicating the success of the reaction.  
We also recorded the CD spectrum of the peptide-conjugated vesicles (Figure 3.9). The 
similarity of the CD spectrum of the pure peptide (Figure 3.9, black trace) and the product from 
the cycloaddition reaction (Figure 3.9, red trace) indicated the presence of the peptide on the 
surface of the polymersomes. We measured the zeta potential and electrophoretic mobility of the 
polymersomes before and after peptide conjugation (Table 3.1). We did not observe any increase 
in the zeta potential – indicating efficient masking of the positive charges on the NLS peptide by 
the aspartic acid residues. 
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Table 3.1. Zeta potential and electrophoretic mobility of polymersomes before and after peptide 
conjugation. 
Formulation Zeta potential (mV) Mobility (µm cm/Vs) 
Polymersomes devoid of peptide -13.8 ± 0.7 -1.08 ± 0.05 
Peptide-conjugated polymersomes -16.6 ± 0.9 -1.3 ± 0.07 
 
3.2.6. Drug Encapsulation in the Polymersomes 
Curcumin (diferuloylmethane) is an extensively studied anticancer and anti-inflammatory 
natural compound. However, curcumin has low water solubility and low bioavailability150. Hence, 
increasing the water solubility and bioavailability of this compound using nanoparticles is a 
promising strategy to enhance the therapeutic potential151. We were not successful in encapsulating 
a significant amount of curcumin in the polymersomes’ hydrophobic bilayer by the solvent 
exchange or thin film rehydration method. Hence, to increase the water solubility, we formed the 
curcumin complex of sulfobutyl-β-cyclodextrin (Captisol)152. To test the complex formation, we 
used seven different concentrations of Captisol solution in water [40, 20, 10, 5, 2.5, 1.25, 0% 
(W/V)] to solubilize the same amount of curcumin (25 mg). The increase in the curcumin solubility 
with the addition of more Captisol indicated the complex formation (Figure B2). We prepared a 
calibration curve by measuring the curcumin absorbance at 429 nm (Figure B3) and determined 
the maximum curcumin solubility to be 2.2 mM. Subsequently, we passively encapsulated the 
hydrophilic Captisol-curcumin complex in the aqueous interior of the polymersomes (Materials 
and Methods). The unencapsulated curcumin complex was removed by size exclusion 
chromatography. Comparing the curcumin absorbance (at 429 nm) before and after gel filtration, 
the encapsulation efficiency was calculated to be 47% (Figure B4A). 
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Figure 3.8. Demonstration of the successful cycloaddition reaction between NLS peptide and 
polymer’s azide group. FT-IR analysis of polymersomes clicked to the peptide, polymersomes 
before the reaction and peptide [analyzing the wavelength range 1600-600 nm (A), and 4000-500 
nm (B)]. Stretches attributed to cyclic ring 1, 2, 3 triazole, and –C≡C are marked. Black trace: 
peptide, red trace: polymersomes, blue trace: polymersomes with the conjugated peptide, pink 
trace: N3-PEG-PLA polymer (the stretch attributed to the azide moiety is marked).  For clarity, the 
spectra are plotted with offsets in the y-axis. 
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Figure 3.9. Confirmation of the peptide conjugation reaction by CD spectroscopy. The similarity 
of spectra of the peptide (black trace) and the peptide-conjugated polymersomes (red trace) 
indicates successful conjugation reaction. The minima for both spectra (197 nm) are marked in the 
plot. 
Doxorubicin is an intercalation agent which induces cell apoptosis in several types of 
malignancies153, 154, 155 (e.g., pancreatic cancer156, human ovarian teratocarcinoma, and human 
breast adenocarcinoma157). To test the simultaneous effect of doxorubicin and curcumin in 
pancreatic cancer cells, we also prepared doxorubicin-encapsulated, peptide-conjugated 
polymersomes by the active pH gradient method (Materials and Methods). The unencapsulated 
doxorubicin was removed from the polymersomes by size exclusion chromatography. We 
calculated the encapsulation efficiency of doxorubicin to be 56% (Figure B4B).  
3.2.7. Demonstration of Contents Release from the Polymersomes and Structural 
Characterization  
We have used the intrinsic difference in reducing agent concentrations in the nucleus and 
cytoplasm118 to trigger content release from the polymersomes. To mimic the intracellular 
environment, we have studied the release profiles of the vesicles in the presence of two different 
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concentrations of the cellular reducing agent glutathione (GSH): 10 mM (mimicking the cytosolic 
environment) and 50 mM (mimicking the nuclear environment). We observed about 15% content 
release of the encapsulated hydrophilic dye calcein in the presence of 10 mM GSH in one hour. 
Increasing the GSH concentration to 50 mM resulted in 70% release of the encapsulated dye 
(Figure 3.10, black trace) in one hour. We also observed that addition of 2 µM MMP-7 enzyme to 
GSH did not affect calcein release from the polymersomes significantly (Figure 3.10, red trace). 
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Figure 3.10. The release profiles of encapsulated calcein from the peptide conjugated 
polymersomes. Calcein release was monitored in the presence of 10 mM and 50 mM GSH (black 
trace). The release was also tested in the presence of both GSH and MMP-7 enzyme (2 µM, red 
trace). Each experiment was repeated four times, and the plots are the average of four release 
profiles. 
In separate experiments, we tested the release of doxorubicin and Captisol-curcumin 
complex from the polymersomes in the presence of the MMP-7 enzyme and GSH (50 µM, 10 or 
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50 mM). We observed that the curcumin-complex encapsulated polymersomes do not significantly 
release their content after treatment with 50 µM and 10 mM GSH. However, adding 50 mM GSH 
triggers 45% release of the curcumin complex from the polymersomes (Figure 3.11 A). Similarly, 
the doxorubicin-encapsulated polymersomes did not show significant release in the presence of 
low GSH concentrations. However, the vesicles released up to 94% of their content in the presence 
of 50 mM GSH (Figure 3.11 B). 
We imaged the polymersomes before and after GSH-triggered contents release by atomic 
force microscopy (AFM, Figure 3.12). We observed that the polymersomes’ spherical shape is 
retained after treatment with 10 mM GSH (Figure 3.12, Panel B). However, treatment with 50 mM 
GSH deformed the vesicles (Panel C), indicating substantial structural changes. 
We also measured the hydrodynamic diameter of the polymersomes before and after 
reduction triggered release employing dynamic light scattering.  We incubated the vesicles 
(average diameter: 143 + 3 nm, Figure 3.7) with 10 and 50 mM GSH for 10 minutes.  We observed 
that treating the polymersomes with 10 mM GSH did not significantly change the size (size: 142 
± 4 nm, PDI: 0.4 ± 0.03, Figure 3.13 A). However, increasing the reducing agent concentration to 
50 mM significantly altered the size distribution and polydispersity of the polymersomes (size: 
308 ± 143 nm, PDI: 0.9 ± 0.08, Figure 3.13 B). The atomic force microscopic images and the 
dynamic light scattering data indicate the disruption of the polymersome after in the presence of a 
high concentration of GSH.  
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Figure 3.11. Drug release profiles from the peptide conjugated polymersomes. The GSH triggered 
release of Captisol-curcumin complex (A) and doxorubicin (B) from the peptide conjugated 
polymersomes (N = 3). Drug encapsulated polymersomes were treated with 50µM GSH + 2 µM 
MMP-7 (black squares), 10 mM GSH + 2 µM MMP-7 (red circles), and 50 mM GSH + 2 µM 
MMP-7 (green triangles). The lines connecting the observed data points are shown on the plots. 
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Figure 3.12. Atomic force microscopic images of the polymersomes (A), after a 10-minute 
incubation with 10 mM GSH (B), and 50 mM GSH (C). 
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Figure 3.13. Hydrodynamic diameters of the peptide conjugated polymersomes after treatment 
with 10 mM (A) and 50 mM GSH (B) (N = 5). 
3.2.8. Demonstration of Polymersomes’ Efficiency in Monolayer Cell Culture 
MMP-7 overexpression has been shown in 98% of human pancreatic cancer tissues158. To 
test the selectivity of our polymersomes, we used the BxPC3 pancreatic cancer cells 
overexpressing the MMP-7 enzyme159. We also used a normal cell line (bEnd-3) as a control group. 
We measured the amount of secreted MMP-7 in the concentrated conditioned media by ELISA 
and observed a significant difference between the BxPC3 (6.9 ± 2.9 ng/mL) and the bEnd-3 cells 
(3.7 ± 1.7 ng/mL).  Subsequently, we compared the cellular uptake of the drug-encapsulated, 
peptide-conjugated and the drug-encapsulated polymersomes devoid of the “masked” NLS peptide 
(Figure 3.14). In this endeavor, we treated the pancreatic cancer cells (BxPC-3) with the 
combination of the curcumin-encapsulated and the doxorubicin-encapsulated polymersomes with 
and without the conjugated peptide on the surface.  We observed that the polymersomes lacking 
the peptide are not significantly transported to the BxPC-3 cell nuclei. However, the peptide-
conjugated polymersomes entered the cell nucleus efficiently (Figure 3.14A). We also tested the 
effect of the tumor microenvironment (presence of secreted MMP-7) on the NLS peptide activation 
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and subsequent cellular internalization of the polymersomes. We observed that the brain 
endothelial cells (bEnd-3), which do not secrete high amounts of MMP-7, failed to internalize the 
peptide-conjugated, drug-encapsulated polymersomes (Figure 3.14B). It is likely that the low 
MMP-7 concentration limits the polymersomes-cell interaction due to the presence of the masking 
domain in the peptide, which neutralizes the positive charges of the NLS.  
 
Figure 3.14. Determination of the cellular uptake and nuclear localization of the polymersomes in 
monolayer cell culture. (A) Uptake was monitored in the BxPC-3 cells and (B) the bEnd-3 cells 
after treatment with the polymersome formulations. The images were obtained with a confocal 
fluorescence microscope. The nuclei were imaged using DAPI, curcumin using FITC and 
doxorubicin using TRITC filter (scale bar: 200 µm, N = 4). 
The buffer-encapsulated polymersomes were non-toxic to both BxPC-3 and bEnd-3 cells 
in vitro (Figure 3.15). To determine the viability, we treated the BxPC3 and the bEnd-3 cells with 
the polymersomes encapsulating Captisol-curcumin complex (27 µM curcumin) and doxorubicin 
(20 µM drug) for 72 hours. We observed that the combination of the two drug encapsulated 
polymersomes containing the peptide on the surface significantly decreased the BxPC-3 cells’ 
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viability (65%) compared to the bEnd-3 cells (88%). The drug-encapsulated polymersomes devoid 
of the peptide was less toxic to the BxPC-3 cells (viability: 87%) and more toxic to the bEnd-3 
cells (viability: 67%).  This reversal may reflect facile endocytosis of the vesicles in the bEnd-3 
cells. In addition, it might be due to faster drug release from the nanoparticles devoid of the 
peptides compared to the peptide-conjugated polymersomes (Figure 3.15).  We also observed that 
the free drugs were more toxic to both the cells compared to the drug-encapsulated polymersomes, 
possibly indicating increased diffusion of the drugs across the cell membrane.  
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Figure 3.15. The viability of the BxPC-3 (red bars) and bEnd-3 cells (green bars) after treatment 
with different polymersome formulations in monolayer cultures (* P ˂ 0.05, N = 6). 
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3.2.9. Demonstration of Polymersomes’ Efficiency in Three-dimensional (3D) Spheroids 
Considering the biochemical and genetic differences between the monolayer cell culture 
and the three-dimensional tumors in vivo160, we cultured the BxPC-3 and bEnd-3 cells as 3D 
spheroids and tested the efficiency of the polymersomes.  We used agar molds capable of 
supporting the growth of 96 uniform size cell spheroids (Materials and Methods). The growth of 
the spheroids was monitored using an optical microscope. The 8-day old spheroids (Figure 3.16) 
were subjected to treatment with four different formulations: a combination of peptide-conjugated 
polymersomes encapsulating curcumin or doxorubicin (containing 27 µM curcumin complex and 
20 µM of the doxorubicin), a combination of polymersomes encapsulating curcumin or 
doxorubicin (without any peptide conjugation), the free drug combination, and the phosphate 
buffer encapsulated polymersomes (plain polymersomes). The control group was treated with 
HBSS, and after 72 hours, the cell viability was determined. We observed that although the drug-
encapsulated polymersomes do not show severe cell toxicity in both cell lines, the drug-
encapsulated, peptide-conjugated polymersomes are significantly more toxic to the BxPC-3 
pancreatic cancer cells (viability: 9%) compared to the normal cells (viability: 36%, Figure 3.16). 
To demonstrate the generality of our approach, the also tested the efficacy of the polymersomes in 
another pancreatic cancer cell line, AsPC-1.  We observed that the drug-encapsulated, peptide-
conjugated polymersomes reduced the viability of the AsPC-1 cells to 22% (Figure B6). 
To further test the efficiency of the formulations in 3D spheroid cultures, we treated another 
set of 8-day old spheroids with the polymersome formulations, encapsulating 27 µM Captisol-
curcumin complex and 20 µM of the doxorubicin, for 72 hours and monitored their growth for 10 
days (Figure 3.17). We observed that the peptide-conjugated, drug-encapsulated polymersomes 
are more toxic toward the BxPC-3 cells (shrinkage of the spheroids up to 49%, Figure 3.17 A, blue 
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triangles) compared to the bEnd-3 cells (shrinkage of spheroids up to 24%, Figure 3.17 B, blue 
triangles). In addition, the polymersomes devoid of the peptide showed less toxicity toward both 
cell spheroids (BxPC-3 cells: up to 54% growth; bEnd-3 cells: up to 44% growth, Figure 3.17, red 
circles) while the free drug combination (containing 27 µM Captisol-curcumin complex and 20 
µM of the doxorubicin) has severe toxicity in both cell lines (shrinkage of spheroids up to 60% in 
bEnd-3 spheroids, and 56% in BxPC-3 spheroids, Figure 3.17, magenta inverted triangles).  We 
also observed that the peptide-conjugated, drug-encapsulated polymersomes shrunk the AsPC-1 
spheroids up to 58% (Figure B7). 
3.3. Conclusions 
The nuclear localization peptides (NLS) are widely used for delivering drugs inside the cell 
nucleus53.  NLS is cell penetrating due to the presence of the positive charges161. However, the 
NLS peptides are non-discriminatory, and the toxicity to the normal cells limits their use in drug 
delivery. We have prepared triggered release polymersomes, armed with a “masked” NLS peptide. 
We have demonstrated that the NLS peptides on the surface of the redox-sensitive polymersomes 
are activated in the presence of high MMP-7 isozyme concentration in the vicinity of tumors. 
Subsequently, the NLS-decorated vesicles penetrate into the cancer cells, enter the nucleus, and 
release the encapsulated cytotoxic drugs in response to the local reducing microenvironment. We 
have demonstrated the efficacy of the polymersomes employing monolayer and three-dimensional 
cultures of pancreatic cancer cells.  We observed that the viability of the cancer cell spheroids is 
reduced to (9.3 ± 0.1)%, and they shrink to (49 ± 23)% in the presence of a combination of 
polymersomes encapsulating doxorubicin or curcumin. The results of this study can contribute to 
the design of polymersome formulations, which are more efficient, compared to the current 
triggered release vehicles for various malignancies, and especially pancreatic cancer. 
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Figure 3.16. Microscopic images of three-dimensional spheroids and their viability after treatment 
with different polymersome formulations. A: Optical microscopic image of 8-days-old BxPC-3 
(a) and bEnd-3 cell (b) spheroids (scale bar: 50 µm). B: The viability of BxPC-3 (red columns) 
and bEnd-3 cells (green columns) after treatment with different polymersome formulations in 3D 
spheroids (* P ˂ 0.05, N = 6). 
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Figure 3.17. Growth curves for the BxPC-3 and bEnd-3 cell spheroids. The 8-day old spheroids of 
BxPC-3 (A) and bEnd-3 cells (B) were treated with different polymersome formulations, and their 
growth was monitored for 10 days (N = 12). Black trace with squares: plain polymersomes; red 
trace with circles: curcumin and doxorubicin encapsulated polymersomes; blue trace with 
triangles: curcumin and doxorubicin encapsulated, peptide-conjugated polymersomes; magenta 
trace with inverted triangles: free drug combination. 
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3.4. Materials and Methods 
3.4.1. Polymer Synthesis and Characterization 
Two types of block copolymers [PEG (2000)-S-S-PLA (6100), N3-PEG (2000)-PLA 
(6000)] (Figure 3.3) have been synthesized applying the ring-opening polymerization and 
characterized in our laboratory7, 19.  
3.4.2. Synthesis and Purification NLS Peptide with an MMP-7 Cleavable “Mask”  
The peptide (hexynoic acid-PKKKRKV-GPMG-IAGQ-EEEE) was synthesized using a 
microwave-assisted, solid phase peptide synthesizer (Liberty Blue, CEM Corporation, Matthews, 
SC) using Fmoc-protected amino acids (ChemPep Inc./Chem-Impex International). The 
synthesized peptide was purified by a reversed phase, high-performance liquid chromatography 
(RP–HPLC, Shimadzu Scientific Instruments) using a diphenyl preparatory column 
(PrinstonSPHER, 10 μm particle size, 300 Å pore diameter, 250 mm × 21.2 mm) as the stationary 
phase. A linear gradient (0-60%) of acetonitrile in water with 0.1% trifluoroacetic acid was used 
as the mobile phase at a flow rate of 10 mL/min over 60 min. The chromatogram was monitored 
using a UV detector at 235 nm (Figure B1 A). The purified peptide was characterized using 
MALDI-TOF mass spectrometry (Applied Biosystems/MDS SCIEX 4800 MALDI TOF/TOF™ 
Analyzer) (Figure B1). 
3.4.3. Enzymatic Peptide Hydrolysis 
The synthesized peptide (1mg/mL) was exposed to the recombinant enzymes (MMP-7, 
MMP-1, and MMP-9, concentration: 2µM) in the presence of 25 mM HEPES buffer (containing 
10 mM CaCl2, 10 mM ZnCl2, pH: 7.5) for 1 hour at room temperature. Subsequently, the circular 
dichroism (CD) spectrometry (Jasco J-815) was used to determine any change in the peptide 
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structure. For the CD experiments, 0.5 mg/mL peptide in phosphate buffer (8 mM), and 1 mm 
path-length quartz cuvette was used. For each spectrum, 30 accumulations were recorded at 25 °C. 
3.4.4. Cloning, Expression, and Purification of MMP-1 and MMP-7 
The catalytic domain of human MMP-1 was cloned in E. coli, and the protein was 
expressed and purified. The coding sequence for the catalytic domain of MMP-1 (amino acid 
sequence: 98-421) was amplified by PCR using the forward and reverse oligonucleotide primers 
as 5′-CCAGGGAGCAGCCTCGTTTGTCCTCACTGAGGGGAAC-3′ (Forward Primer), 5′-
GCAAAGCACCGGCCTCGTTATTTGGACTCACACCATGTGTTTTCCA-3′ (Reverse 
Primer).  The PCR amplified DNA fragment was cloned into the LIC-His vector and transformed 
into TOP10® cells (Invitrogen). MMP-1 was expressed and purified from E. coli BL21 (DE3) 
Star® (Invitrogen). Like other MMPs, MMP-1 was found to be confined in the inclusion bodies 
from where it was purified by solubilizing in buffer (50 mM Tris-HCl, pH 7.5) containing 6 M 
Urea, 10 mM CaCl2 and 10 µM ZnCl2 followed by subjecting the suspension to serial dialysis 
against the above buffer with decreasing concentration of urea as described by Tobwala and 
Srivastava162. The folded protein exhibited high catalytic activity and showed a predominant band 
on SDS-PAGE.  The cloning, expression, and purification of human MMP-7 were performed as 
described by Ganguly et al163. 
3.4.5. Polymersome Preparation 
We used the solvent exclusion method3 to prepare the polymersomes. Briefly, the 
polymers, PEG-S-S-PLA, and N3-PEG-PLA were dissolved in tetrahydrofuran (THF) in a 60:40 
molar ratios respectively. 5 mg of the polymer solution was added dropwise, while stirring, to 5 
mL phosphate buffer (25 mM, pH 7.4) to have a 1mg/ml suspension of polymers. Subsequently, 
the organic solvent was evaporated by gentle air flow for 45 minutes. The resulted polymersome 
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solution was then subjected to bath sonication (Aquasonic, 250D, power level 9) for 45 minutes at 
room temperature. Similar procedure was applied in the preparation of calcein encapsulated 
polymersomes. In the latter case, the polymer solution was added to a 10 µM calcein solution 
prepared in the phosphate buffer (25 mM, pH 7.4). 
3.4.6. Polymersome-Peptide Conjugation and Characterization 
The Copper (II)-catalyzed azide-alkyne cycloaddition (“Click” reaction) was used to form 
the peptide-polymersomes conjugate. The polymersome solution (1 mg/mL polymer 
concentration) was mixed with the pure peptide (1:3 molar ratio of azide: alkyne). Copper (II) 
complex (10 μL of 0.053 M aqueous solution, prepared by mixing an aqueous solution of CuCl2, 
0.53 mmol, and N,N,N′,N′,N′′-pentamethyldiethylenetriamine, PMDTA, 2.1 mmol), and sodium 
ascorbate (10 μL of 27 mg/mL aqueous solution, 1.4 μmol) was added to the mixture and stirred 
overnight at room temperature164.  The non-conjugated peptides were separated from the 
polymersome solution by dialyzing (molecular weight cut off 3500-5000 Da) against phosphate 
buffer (25mM, pH 7.4) with similar osmolality for 5 days at 4 °C. To verify peptide conjugation, 
the dialyzed solution (0.4 mg/mL) was subjected to CD spectrometry (8 mM Phosphate buffer, 
pH: 7.4). A quartz cuvette (1 mm path length) was used in the CD experiments, and 30 
accumulations were recorded in each case.  
The peptide conjugation was further confirmed by Fourier Transform Infrared 
spectroscopy (FTIR). A ThermoNicolate, Nexus, 870 spectrometer with a KBr beam splitter in the 
spectral range of 4000 - 400 cm-1 were used at a spectral resolution of 4 cm-1 using a mirror velocity 
of 0.158 cm/s. The experiment was conducted using the transmission accessory. Samples were 
prepared in the form of pallets using NaCl window. Samples were placed in the universal sample 
holder for performing the experiment.  
 70 
 
3.4.7. Sulfobutyl-β-cyclodextrin (Captisol) - Curcumin Complex Formation 
Curcumin (Alfa Aesar, 95% curcuminoid) was solubilized in water in the presence of 
Captisol (Cydex) according to a reported procedure by the manufacturer 
(http://www.captisol.com/faq/how-to-solubilize-a-drug-with-captisol/). Briefly, 40% captisol 
solution was prepared in water, mixed with solid curcumin (92 mg/mL), and stirred in the dark at 
room temperature for 3 days. Subsequently, the suspension was filtered to remove any non-
complexed curcumin.  
3.4.8. Preparation of Drug Encapsulated Polymersomes 
We prepared two different polymersome formulations encapsulating doxorubicin or 
curcumin-Captisol complex. For doxorubicin encapsulation, we have used the active pH gradient 
method7, 19. Briefly, we have prepared the polymersomes using the solvent exchange method in 
citrate buffer (20 mM, pH 4.0). Subsequently, the pH of the external buffer was increased to 7 by 
adding aqueous sodium bicarbonate solution (2M). Doxorubicin hydrochloride (Bridge 
Bioservices) was added (0.2 mg/mL of polymersomes) to the polymersome solution and stirred 
for 1 hour at room temperature. The non-encapsulated doxorubicin was separated from the 
polymersomes encapsulating the drug using size exclusion chromatography (Sephadex G-100, GE 
Healthcare). The encapsulation efficacy was estimated by comparing the recorded absorbance 
spectra of the polymersomes before and after gel filtration.  
The curcumin-Captisol complex encapsulated polymersomes were prepared applying the 
passive encapsulation method, by adding the polymer solution to the curcumin-captisol complex 
solution. The non-encapsulated complex was removed by passing the polymersomes through a 
Sephadex G100 gel filtration column. The encapsulation efficiency was calculated by comparing 
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the absorption spectra of the Captisol-curcumin encapsulated polymersomes with that of the 
Captisol-curcumin complex.  
3.4.9. Size-Distribution and Morphology of the Polymersomes 
The hydrodynamic diameter of the polymersomes (1 mg/mL polymer concentration) was 
determined by dynamic light scattering method using a Zeta Sizer instrument (NanoZS 90, 
Malvern Instruments). Ten measurements per sample (four repeats) were performed using 
disposable polystyrene cuvettes, at 90° scattering angle, and the equilibration time was set at 30 
seconds for all measurements.  Transmission electron microscopy (TEM) was used to verify the 
structure of the polymersomes. Negatively stained polymersomes were imaged applying a TEM 
microscope (JEOL JEM 2000). 
3.4.10. Determination of the Concentration of Cell Secreted MMP-7 
The conditioned media from BxPC-3 and bEnd-3 cells were collected and subsequently 
concentrated (10 times) using centrifugal devices (PLL, MWCO: 3000 Da). The concentration of 
MMP-7 was estimated using a commercially-available MMP-7 ELISA kit (RayBiotech) following 
the manufacturer’s protocol.  
3.4.11. Release Studies from the Polymersomes 
We determined the release of encapsulated calcein (10 µM) in the presence of different 
concentrations of added reducing agent (GSH, 10 mM, and 50 mM). For the release studies, we 
prepared the dye-encapsulated polymersomes and subsequently, conjugated the peptide. After 
conjugation, the fluorescence of the unencapsulated calcein was quenched by 10 mM CoCl2. The 
release of the encapsulated calcein was determined by monitoring the reduction in fluorescence 
emission in the presence of added GSH. The experiments were conducted using a 96-well 
microplate reader (Spectramax M5, Molecular Devices; excitation: 495 nm, emission: 515 nm), 
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and the release was monitored for 30 minutes after each GSH addition. We also determined the 
release of encapsulated calcein in the presence of added MMP-7, MMP-9, and MMP-1 (2 µM) 
without the added GSH (Figure S5). 
The release of the drugs (curcumin and doxorubicin) was also tested in the presence of 
reducing agent. Polymersomes loaded with the drug and were dispensed into a dialysis tube 
(Spectra/Por Float-A-LyzerG2, MWCO: 3.5-5 kD). The GSH (final concentration 50µM, 10mM, 
or 50mM) and MMP-7 enzyme (2µM) were added to the polymersome solution, and the release 
of drug was monitored for 30 minutes after each GSH treatment by UV spectrometry (doxorubicin 
release was monitored at 483 nm, and curcumin complex at 429 nm). The percent release of the 
drug from the polymersomes was then calculated.  
3.4.12. Atomic Force Microscopic (AFM) Imaging 
Polymersomes (1 mg/mL) were treated with 0, 50 µM and 10 mM final concentration of 
GSH. The samples were prepared by incubating 10 µL of each solution on silicon substrates 
(University Wafer) for 10 min in a sealed compartment to prevent evaporation at room 
temperature. The samples were then washed with de-ionized water (Millipore) repeatedly, and 
dried under purified air flow. The imaging measurements were performed using a commercial 
atomic force microscope (NT-MDT NTEGRA AFM). The samples were imaged under ambient 
conditions in semi-contact mode using an AFM tip with a resonant frequency of 190 kHz (Budget 
sensors).    
3.4.13. Cell Culture 
The BxPC-3 and AsPC-1 cells (human pancreatic adenocarcinoma, ATTC), were cultured 
in RPMI-1640 complete growth medium (containing 10% fetal bovine and 1% antibiotic-
antimycotic solution, devoid of phenol red) in 75 cm2 tissue culture flasks incubated at 37 °C in a 
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humidified atmosphere and 5% CO2. The bEnd-3 cells (brain endothelial, ATTC) were cultured in 
DMEM complete medium (devoid of phenol red) under the same conditions. 
3.4.14. Nuclear-Targeting Studies 
The peptide-conjugated polymersomes encapsulating doxorubicin or curcumin and 
polymersomes encapsulating doxorubicin or curcumin but devoid of the peptide were used to 
assess the nuclear targeting in the BxPC-3 and bEnd-3 cells. The concentration of the 
polymersomes was the same (0.02 mg/mL polymer) for all the experiments. After the cultured 
cells had been 90% confluent, they were trypsinized and subcultured in 96 well plates (5,000 
cells/well). After 12 h, the cells were treated with each formulation (0.02 mg/mL for 1 hour), the 
nucleus was stained with HOESCHT 33342 dye (Enzo Life Sciences), the cells were washed 
gently 4 times with sterile HBSS buffer, and subsequently imaged using a fluorescent microscope 
(Olympus IX81 motorized inverted fluorescent microscope). The 20X objective was used to image 
the cells and DAPI, FITC, or TRITC filters were used according to the samples.  
3.4.15. Three-Dimensional (3D) Spheroid Cell Culture 
The three-dimensional (3D) spheroids of all cell lines (BxPC-3, AsPC-1, and bEnd-3) were 
prepared using an agar mold containing 96 microwells. The mold was cast using a 3D Petri Dish® 
(Microtissues, natural 3D) in a sterile condition, washed 3 times, and equilibrated with an 
appropriate cell culture medium overnight. The following day, 10,000 cells were seeded in each 
microwell according to the manufacturer’s guideline. The growth of the spheroids was monitored 
under a microscope, and the media was changed carefully as needed. 
3.4.16. Cell Viability Studies (Two-Dimensional Cell Culture) 
The confluent bEnd-3 and BxPC-3 cells were sub-cultured in 96 well cell culture plates. 
After overnight growth, the cells were divided into 4 treatment groups and treated for 72 hours at 
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37 oC. (1) The Control group was treated with phosphate buffer encapsulated polymersomes. (2) 
Sample 1 was treated with curcumin complex and doxorubicin encapsulated polymersomes 
(containing 27 and 20 µM of the drugs respectively). (3) Sample 2 was treated with peptide 
conjugated polymersomes encapsulating curcumin complex and doxorubicin (containing 27 and 
20 µM of the drugs respectively). (4) Sample 3 was treated with free drug combination containing 
both curcumin complex (27 µM) and doxorubicin (20 µM). Each experiment was repeated 6 times. 
Afterward, the cells were washed, and the viability was determined using the Alamar Blue assay 
(Life Technologies) following the manufacturer’s protocol. The fluorescence intensity of the 
resorufin was measured using a spectrofluorometer (excitation: 560 nm, emission: 590 nm). 
3.4.17. Cell Viability Studies (Three-Dimensional Culture) 
A modified Alamar Blue assay was used to assess the viability of the bEnd-, AsPC-1 and 
BxPC-3 cells in the spheroids. The 8-days old spheroids were treated with the same formulations 
as the monolayer cultures (described in the previous paragraph). After 72 hours, the spheroids were 
dislodged from the agar molds by centrifugation, agitated and trypsinized to form single cells, and 
cultured overnight in a 96 well cell culture plate (6 repeats). The following day, Alamar Blue was 
added to the wells, and resorufin fluorescence was monitored.  
We determined the effect of the drugs and on the growth of the 3D spheroids. The 8-day 
old spheroids (12 repeats in each group) were treated with the polymersome formulations for 72 
hours at 37 °C.  The spheroids were washed with phosphate buffer saline, and their growth was 
monitored for another 10 days. The spheroid images were analyzed using the Image J software, 
and the percentage growth rate was calculated.   
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4. TARGETED CYTOPLASMIC CALCIFICATION: A DRUG-FREE, 
POLYMERSOMAL PROSTATE CANCER THERAPY4 
 
 
Figure 4.1. Graphical abstract. 
4.1. Introduction 
Cancer is one of the most lethal diseases around the world. Based on the American Cancer 
Society estimation, 1,688,780 new cancer cases will be diagnosed, with 600,920 deaths in the US 
during 2017. Among the various types of malignancies, prostate cancer is the second leading cause 
of death, especially for men older than 65 years (based on American Cancer Society report). 
                                                 
 
4 This section is coauthored by Tayebeh Anajaﬁ, Abbas Sedigh, Seungyong You, Manas K. Haldar, Yongki Choi, D. 
K. Srivastava, and Sanku Mallik. Tayebeh had primary responsibility to conduct all the experiments, analyze the 
data in and write the manuscript. Abbas assisted in testing the efficacy of polymersomes. Jamie imaged the 
polymersomes using AFM. Manas synthetized the polymers. Drs. Choi, Srivastava and Mallik verified the data and 
advised on experimental designs. 
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Conventional treatment options for prostate cancer includes surgery, chemotherapy, radiation 
therapy, and a few others (hormone therapy, vaccine treatment). Most of these treatments have 
many side effects, which decrease the quality of life of the patients. Development of new 
technologies with lower side effects is required to treat this devastating disease in the early stages.  
Targeted therapy offers the hope of treating cancer with minimum effect on the healthy 
cells. Both passive and active targeting strategies alter the bio-distribution of therapeutics165. The 
passive targeting utilizes the presence of leaky vasculature in the tumor tissues to deliver 
nanoparticles loaded with the drug of choice165. Furthermore, the drainage of the cancer tissues is 
also defective, resulting in the retention of the nanoparticles in the tumor sites [the Enhanced 
Permeation and Retention (EPR) effect115]. In active targeting strategy, the presence of a particular 
protein on the plasma membrane helps to concentrate the nanoparticles in the malignant cells166.  
Prostate Specific Membrane Antigen (PSMA)167 is an excellent cell surface protein for 
targeting the prostate cancer. PSMA is overexpressed about one thousand times85 on the surface 
of prostate cancer cells and solid tumors neovasculature. This receptor is capable of taking up 
folate via receptor-mediated endocytosis through clathrin-coated pits85, 86.  
Intracellular calcium ion homeostasis (Figure 4.2) is a complex, finely regulated, and vital 
mechanism for proper cell function, gene expression, apoptosis regulation, heart muscle 
contraction, etc. Intracellular calcium ion concentration (~ 100 nM)168 maintenance is the result of 
the cooperation of various calcium channels and transporters located on the cellular, 
mitochondrial, and endoplasmic reticulum membranes87. Transient changes in cytoplasmic 
calcium ion concentration stimulates calcium signaling. However, the elevated calcium ion levels 
are lowered quickly to maintain the intracellular calcium homeostasis. Dysregulation of calcium 
ion homeostasis is toxic to the cells and triggers apoptosis via several pathways169 (Figure 4.3). 
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Hence, intentionally disturbing the calcium ion homeostasis and stimulating calcium crystal 
formation could lead to cell death. Zhao et.al have reported that folic acid’s carboxylate groups 
induce the nucleation of calcium crystals on the surface of HeLa cells88.  
 
 
Figure 4.2. Intracellular calcium ion homeostasis. Calcium ion uptake from the extracellular 
environment occurs through various Ca2+ channels [e.g., Voltage-gated (VG) channels, Receptor 
gated (RG) channels, and Ca2+ release activated Ca2 + (CRAC) channels]. Intracellular Ca2+ can be 
transported to the endoplasmic reticulum (ER) via sarcoendoplasmic reticulum Ca2+ ATPase 
(SERCA) pump. The Ca2+ binding protein calsequestrin stores Ca2+ inside the ER. Interaction of 
the inositol-1,4,5- trisphosphate receptors (IP3R) with its ligand triggers calcium ion release from 
the ER. Mitochondria is another Ca2+ storage organelle in the cells. In this organelle, Ca2+ uniporter 
opens up because of an increase in the cytoplasmic [Ca2+]. In the other hand, Ca2+/Na+ and Ca2+/H+ 
exchangers are gates for Ca2+ release from the mitochondria. Plasma membrane calcium ATPase 
(PMCA), and Ca2+ion exchangers are the cytoplasmic calcium export systems embedded on the 
cell’s plasma membrane.  
Polymersomes13 are spherical polymeric bilayers, with an aqueous interior. These nano-
vesicles can encapsulate both hydrophobic and hydrophilic compounds and carry them to their site 
of action with the minimum leakage during their journey170. Conjugation of targeting groups on 
the surface localizes the polymersomes at the intended sites. Selection of appropriate block 
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copolymers renders the vesicles as biocompatible and biodegradable. Incorporating stimuli-
responsive groups in the block copolymers allows spatial and temporal control over the contents 
release from the vesicles171. The intrinsic difference between the cytoplasmic and plasma oxidative 
states109 is an excellent stimulus for releasing the polymersomal contents inside the cells. Higher 
concentration of reducing agent glutathione (GSH) in the cytoplasm (10 mM vs 50 µM in 
extracellular environment) stimulates the reductive cleavage of the disulfide bonds of the 
copolymers, resulting in the rapid release of the encapsulated drugs from the vesicles172.  We have 
recently used the higher reducing agent concentration to deliver anticancer drugs selectively to cell 
nuclei. 
 
Figure 4.3. The increase in the cytoplasmic Ca2+ concentration could be the result of environmental 
or genetic stress173, 174. Calcium ions are imported to the cytoplasm through various Ca2+ channels 
or released from its intracellular storages (ER and mitochondria). Calcium overload in the 
mitochondria induces the formation of PTP (Permeability Transition Pore)175 which leads to loss 
of mitochondrial membrane potential (ΔΨ) followed by the release of mitochondrial enzymes (e.g., 
cytochrome C)173 which promotes cell death. Furthermore, increased cytoplasmic calcium 
concentration can be sensed by calpain which leads to lysosomal rupture, caspases activation176, 
and increase in autophagy174.  
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In the present study, we have used folate presenting, redox sensitive polymersomes to 
target the prostate cancer cells overxpressing the PSMA receptor on the surface. The 
polymersomes encapsulate a high concentration calcium chloride (50 mM CaCl2). Reduction-
triggered release of the encapsulated CaCl2 in the cytoplasm, in presence of folic acid, causes the 
formation of calcium crystals and dysregulation of calcium homeostasis, leading to apoptosis of 
the targeted prostate cancer cells.  
4.2. Materials and Methods 
4.2.1. Polymer Synthesis and Characterization 
A disulfide-linked block copolymer [PEG (1900)-S-S-PLA (6100), Figure 4.4A] was 
synthesized by the ring opening polymerization in our laboratory. The synthesized polymer was 
purified and characterized by nuclear magnetic resonance spectroscopy19, 172. A commercially 
available (Nanocs Inc.) folate conjugated-phospholipid PEG derivative (DSPE-PEG (2000)-
folate) was also used in the preparation of the vesicles (Figure 4.4B). 
 
Figure 4.4. Structures of (A) PEG (2000)-S-S-PLA (6100), and (B) DSPE-PEG (2000)-folate. 
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4.2.2. Polymersome Preparation 
The solvent exchange method was used to prepare the polymersomes3. The polymer to 
lipid molar ratio was set at 95:5. Briefly, the folate-conjugated lipid was added to the polymer 
solution (in tetrahydrofuran, THF). The resultant solution was added dropwise to a phosphate 
buffer (pH: 7.4) containing 50 mM calcium chloride (CaCl2) to make a 1 mg/mL polymersome 
solution. The organic solvent then was removed by blowing air through the solution for 45 minutes. 
Removal of the organic solvent aids the polymersome formation177. Subsequently, the solution 
was sonicated (Aquasonic, 250D, power level 9) for one hour at room temperature. The 
unencapsulated CaCl2 was removed from the polymersomes using a cation exchange resin (Dowex 
HCR-W2). We used the same strategy for preparing the calcein encapsulated polymersomes.  
Calcein (10 µM) was encapsulated into the aqueous core of the polymersomes using the passive 
encapsulation method3. 
For the polymersomes containing the 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(Lissamine rhodamine B sulfonyl, ammonium salt), we used a molar ratio of polymer: lipid: 
lissamine rhodamine as 90: 5: 5 respectively. The polymer and the folate lipid were mixed with 
the lissamine rhodamine lipid in THF, and the solution was added dropwise to the aqueous buffer 
followed by air blowing and sonication (described in the previous paragraph). 
 4.2.3. Size-distribution of the Polymersomes 
The hydrodynamic diameter of the polymersomes was determined by dynamic light 
scattering (DLS) employing a zeta sizer instrument (NanoZS 90, Malvern Instruments) at 90° 
scattering angle. The solutions of the different polymersome solutions (1 mg/mL total polymer) 
were used, and 10 measurements per sample was monitored (four repeats). Disposable polystyrene 
cuvettes were used and equilibration time was set to 60 seconds.  
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4.2.4. Atomic Force Microscopy Imaging 
Polymersome morphology was investigated using Atomic Force Microscopy (AFM)172.  
AFM scans were carried out in non-contact mode at a scanning rate of 0.7 Hz and a resonance 
frequency of 145 kHz using an NT-MDT NTEGRA (NT-MDT America, Tempe, AZ). The 
scanning areas were 5 m x 5 m at the resolution of 512 points per line, respectively.  The 
polymersome solution was dropped on top of a silicon chip. The dropped solution was left at room 
temperature for 10 minutes. The remaining solution was blown away with an air-blow gun. For 
the GSH treated polymersome samples, the GSH solution was added into polymersomes to have a 
final concentration of 10 mM GSH, and the mixture was incubated for 10 minutes. 
4.2.5. Calcium Chloride Encapsulation Measurement 
To test the amount of encapsulated CaCl2 in the polymersomes, we used Triton-X100 to 
disrupt the vesicles.  Subsequently, we used a calcium colorimetric assay kit (BioVision) to 
measure the amount of CaCl2 released from the disrupted polymersomes.  
4.2.6. Release Studies 
We used the calcein-encapsulated polymersomes (40 µl, 1 mg/mL) to demonstrate 
reduction-triggered release of the contents. The fluorescence from the unencapsulated calcein was 
quenched using a high concentration of a quencher (CoCl2, 10 mM). The decrease in the calcein 
fluorescence (excitation: 495 nm, emission: 515 nm) from polymersomes was monitored using a 
96-well plate reader (Spectramax M5, Molecular Devices) for 40 minutes in the presence of 50 
µM glutathione (GSH). Subsequently, the release was monitored for another 40 minutes in the 
presence of 10 mM GSH.  
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4.2.7. Cell Culture 
Human Embryonic Kidney 293 cells (HEK-293, ATTC) were cultured in Dulbecco’s 
modified Eagle’s (DMEM) medium supplemented with fetal bovine serum (10%), and antibiotic-
antimycotic solution (1%). Human prostate adenocarcinoma cells (LNCaP, ATTC) were cultured 
in RPMI-1640 complete growth medium supplemented with the same components. Both cell lines 
were incubated at 37°C, 5% CO2, in a humidified atmosphere.  
4.2.8. Crystal Formation 
For the crystal formation studies, we used cell culture media (DMEM) containing 500 
µg/mL folic acid and 50 mM CaCl2. After 24 hours incubation, brightfield images of crystals was 
recorded using a microscope (Olympus IX81 motorized inverted fluorescence microscope).   
4.2.9. Cellular Uptake Study 
To study the role of PSMA in the active targeting, we tested the uptake of the 
polymersomes with two different cell lines.  For the ease of visualization, we incorporated a lipid 
with the lissamine rhodamine dye (5% molar ratio) in the bilayer of the polymersomes presenting 
folate on their surface. The LNCaP and HEK-293 cells were sub-cultured in 96 well plates. Once 
the cells were confluent, the polymersomes were incubated with the cells, and the nuclei were 
stained with Hoechst 33342 dye (Enzo Life Sciences). Subsequently, the cells were washed with 
cell culture media (phenol red free), and the uptake of the polymersomes were monitored using 
20X objective of a fluorescence microscope. 
4.2.10. Spheroid Cell Culture 
We cultured the LNCaP and HEK-293 cells in agar molds. The molds were constructed 
using 3D petridishes (Microtissues, natural 3D). Each petridish has the capacity to grow 96 cell 
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spheroids. After equilibrating the agar molds with the appropriate cell culture media (DMEM or 
RPMI), 10,000 cells were cultured in each petridish. The cells then were incubated at 37°C in a 
humidified atmosphere. After 2 days, the spheroids formed, and we replaced the media with fresh 
media every other day. The growth of the spheroids was monitored using light microscopy.  
4.2.11. Cell Viability Studies (Monolayer Culture) 
For the viability studies, we subcultured the HEK-293 and LNCaP cells in 96 well culture 
plates. After 12 hours, the culture media was replaced with a media containing 500 µg/mL folic 
acid (HBSS was added to control wells) and incubated for 15 minutes. Following the incubation, 
the cells were treated with the polymersomes encapsulating CaCl2. The treated cells were then 
incubated at 37 °C for 24 hours. The cells were subsequently imaged using light microscopy, and 
the viability was tested using Alamar Blue assay (Life Technologies). The fluorescence intensity 
of the reduced form of resazurin was measured using spectrofluorometery (excitation: 560 nm, 
emission: 590 nm). 
4.2.12. Cell Viability Studies (Three-Dimensional Culture) 
We used the 7-day old spheroids (Figure 4.5) to study the viability after treating with the 
polymersome formulations. We used four different treatment groups, the control (no treatment), 
folic acid treatment (media containing 500 µg/mL), polymersomes encapsulating Ca2+ ions (0.04 
mg/mL), and folic acid + polymersomes encapsulating Ca2+ ions. The culture media were removed 
and replaced with fresh media (control) or media containing the appropriate treatment. The 
spheroids were incubated at 37°C for 24 hours and then the media was removed. To check the cells 
viability, we dislodged the cells from the molds and triturated them to make single cell 
suspensions. Subsequently, the cells were cultured in 96 well plates (6 repeats each treatment 
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group) and incubated overnight. Then Alamar Blue assay was used to determine the viability of 
cells in each treatment group.  
 
Figure 4.5. Seven-day-old spheroids of (A) HEK-293 cells, and (B) LNCaP cells. The scale bar 
is showing 50 µm. 
4.2.13. Spheroids Growth Curve 
We studied the effect of different treatments on the spheroid’s size. We designed the 
experiments with the same treatment groups as mentioned in the previous section. We monitored 
the growth of spheroids from the second day. On the seventh day, the spheroids were treated with 
the polymersomes. After 24 hours, the media was changed and we monitored the growth of the 
spheroids for 15 days. The percentage change in the spheroid size was calculated and the growth 
curve was plotted. 
4.2.14. Mitochondrial Membrane Permeability (MMP) Assay 
Confluent LNCaP cells were incubated with targeted polymersomes encapsulating calcium 
chloride supplemented with folic acid for 24 hours at 37 °C. Subsequently, the cells were washed 
with HBSS buffer and stained with 200 nM tetramethylrhodamine methyl ester (TMRM, 
Molecular Probes) for 30 minutes at 37 °C. Cells were the harvested and analyzed by flow 
cytometry using a BD Accuri™ C6 flow cytometer.  Fluorescence intensity of TMRM-stained 
cells (20,000 cells per sample) was measured using the FL2 channel.  
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4.3. Results and Discussion 
4.3.1. Polymer Synthesis and Characterization 
The ratio of the hydrophilic part to the total mass of the copolymer (f value)13 was 
considered in preparing the building blocks of the polymersomes. We synthesized the reduction-
sensitive block copolymers (Figure 4.4A) with an f value of 0.24. The incorporation of a disulfide 
bond between the hydrophilic polyethylene glycol (PEG) and the hydrophobic polylactic acid 
(PLA) blocks endows reduction response to the polymers (Figure 4.4A). Polyethylene glycol 
(PEG) was used as the hydrophilic block to decrease the uptake of the polymersomes by the 
reticuloendothelial system and increase the biocompatibility and water solubility178. The PEG 
layer also increases the circulation time of the polymersomes179. Polylactic acid (PLA) is a 
biocompatible polymer180, and was used as the hydrophobic block in our studies.  
4.3.2. Crystal Formation in Cell Culture Media 
Incubating the cell culture media for 24 hours containing 500 µg/mL folic acid with CaCl2 
(50 mM), resulted in the formation of calcium phosphate crystals, which were visualized using 
light microscopy with 20X magnification (Figure C1). 
4.3.3. Polymersome Preparation and Characterization 
The polymersomes were designed to have the ability to target the cancer cells 
overexpressing the PSMA receptor on the cell membrane. Hence, we incorporated 5 mole% of 
DSPE–PEG (2000)–folate lipid (Figure 4.4B) in the polymersome bilayer. The inherent reducing 
environment in the cell cytoplasm181 was used to trigger content release from the polymersomes 
in the cytoplasm. Therefore, 95 mole% of the polymersome bilayer was made of the synthesized 
PEG-S-S-PLA copolymer. The polymersomes were prepared using the solvent exchange method 
(Materials and Methods). Based on dynamic light scattering, the average hydrodynamic diameter 
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of the polymersomes was (94 ± 18) nm, and the polydispersity was (0.5 ± 0.01) (Figure 4.6). 
Atomic force microscopy (AFM) imaging revealed the spherical structure of the polymersomes 
(Figure 4.8A).   
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Figure 4.6. Size distribution of the polymersomes measured by dynamic light scattering. The 
hydrodynamic diameter of the polymersomes was (94 ± 18) nm, and polydispersity of 0.5 ± 0.01 
(N=4). 
4.3.4. Calcium Chloride Encapsulation in the Polymersomes 
Calcium chloride (CaCl2) was successfully encapsulated in the polymersomes aqueous 
core. To measure the encapsulation efficacy, the polymersomes were treated with Trition-X100 to 
disrupt the bilayer of the vesicles. The amount of CaCl2 was then quantified by forming a 
chromogenic complex with o-cresolphthalein. Absorption of the complex was measured at 575 
nm. The encapsulation efficacy (27 ± 1)% was calculated by comparing the absorption of the 
complex with a standard curve (Figure C2).  
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4.3.5. Reduction-Triggered Content Release from the Polymersomes 
Human plasma has a more oxidative environment (reducing agent concentration: 10-40 
µM)19, 182 compared to the cell cytoplasm (glutathione concentration 5 – 10 mM)109,181. We used 
this intrinsic difference in reducing agent concentration to trigger the release of polymersome 
contents. The release of encapsulated dye calcein was monitored using fluorescence spectrometry 
in the presence of 0, 50 µM, and 10 mM GSH. We observed about 6% release from the 
polymersomes after 80 minutes in the absence (Figure C3) or in the presence of 50 M GSH 
(Figure 4.7). However, the addition of 10 mM GSH, to mimic the cell cytoplasm reductive 
environment, caused a burst content release of 23% from the polymersomes (Figure 4.7). 
Furthermore, the structure of the polymersomes was imaged in the presence of 10 mM GSH 
employing AFM.  As shown in the Figure 4.8C, treating with 10 mM GSH quickly deformed the 
vesicles. 
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Figure 4.7. Triggered release of encapsulated calcein from the polymersomes. Calcein release 
was monitored in the presence of 50 µM and 10 mM GSH (N = 6) employing fluorescence 
spectroscopy (Ex: 495 nm, Em: 515nm). 
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4.3.6. Monolayer Cell Cultures 
To demonstrate the active targeting, we treated the PSMA positive (LNCaP), and PSMA 
negative (HEK-293) cells with polymersomes incorporating the fluorescent lissamine rhodamine 
lipid (Ex/Em: 560/583 nm) in their bilayer. This dye is visualized employing the TRITC filter in 
a fluorescence microscope. The imaging experiments revealed that the polymersomes (after 1 hour 
incubation) effectively enter the PSMA positive cells (LNCaP cells) and not the HEK-293 cells 
(Figure 4.9).  
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Atomic force microscopy (AFM) images of polymersomes before (A-B) and after 
treatment with 10 mM GSH (C-D). Polymersomes’ spherical shape is visible in Panels A and B, 
and the doformations  in Panels C and D. 
To test the toxicity of the formulations in monolayer cell culture, we performed the Alamar 
Blue assay (Figure 4.10). The results indicated that the calcium ion encapsulated, targeted 
polymersomes in combination with folic acid is more toxic to the cancer cells (LNCaP) 
overexpressing the PSMA receptor. However, the same formulation has lower toxicity to the non-
cancerous cells (HEK-293) lacking the PSMA receptor on the surface. On the other hand, in the 
absence of folic acid, the formulation has less toxicity to both cells lines, possibly due to lack of 
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calcium micro-crystal formation88. The viability was more than 80% for both cells (HEK-293 cells: 
85 ± 11%, LNCaP cells: 90 ± 17%) in the presence of the targeted polymersomes encapsulating 
calcium chloride.  However, the same polymersomes, in the presence of folic acid, decreased the 
cell viability to 55 ± 18% and 34 ± 10% for the HEK-293 and LNCaP cells, respectively. 
Moreover, the non-targeted formulation did not show significant toxicity in both cell lines, 
indicating the successful targeting strategy (Figure 4.10). 
 
Figure 4.9. Fluorescence microscopic images of the HEK-293 (Panels A-C) and LNCaP cells 
(Panels D-F) treated with polymersomes presenting folic acid on the surface for 1 h. The cells 
nuclei are stained with HOESCHT 33342 dye and are imaged using the DAPI filter (A and D). 
Red fluorescence is originating from the lissamine rhodamine dye incorporated in the bilayer of 
the polymersomes. TRITC filter is used to image the polymersomes (B and E). The Panels C and 
F are showing the merged images (scale bars: 25 μm).  
4.3.7. Three-dimensional (3D) Spheroids 
There are significant differences between the conventional two-dimensional cell culture 
and the in vivo tumors. For example, the cells in the tumor’s core are necrotic and hypoxic, which 
confers resistance to chemo and radiotherapy183. The three-dimensional spheroids resemble the 
tumors more than the conventional monolayer cells184. We cultured the HEK-293 and LNCaP cells 
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as spheroids using agar molds. Subsequently, the 7- day-old spheroids were treated with different 
formulations including phosphate buffer, folic acid, polymersomes encapsulating CaCl2, 
polymersomes encapsulating CaCl2 supplemented with folic acid, and non-targeted polymersomes 
supplemented with folic acid. After 24 hours, the media was replaced with fresh media. The 
spheroids were dislodged from the agar molds and disrupted by extensive trituration. The cells 
were then subcultured in 96 well plates and incubated overnight. The Alamar Blue assay was then 
performed to measure the toxicity of different formulations in spheroid cultures of the cells 
(Figure4.11).  The viability was 96 ± 9% for HEK-293 cells and 65 ± 4% for LNCaP cells in the 
presence of targeted polymersomes encapsulating calcium chloride.  However, the same 
polymersomes, in the presence of added folic acid, decreased the cell viability to 59 ± 7% and 38 
± 4% for the HEK-293 and LNCaP cells, respectively. The targeted polymersomes were more 
toxic to the LNCaP cells compared to the HEK-293, demonstrating the effect of active targeting. 
In a separate experiment, we formed HEK-293 and LNCaP cell spheroids and monitored 
their growth for 15 days. On the seventh day, we treated the spheroids with four different 
formulations including phosphate buffer, folic acid, polymersomes encapsulating CaCl2, and 
polymersomes encapsulating CaCl2 supplemented with folic acid. The spheroids were incubated 
at 37°C for 24 hours. Subsequently, the media was replaced with new media to remove the 
treatments and the spheroid’s growth was monitored for eight more days. Percent change in the 
size of the spheroids is shown in Figure 4.12. The formulations did not affect the growth of the 
HEK-293 cell spheroids (Figure 4.12A). We observed that the polymersomes encapsulating CaCl2 
supplemented with folic acid have the highest ability to shrink the LNCaP micro-tumors (43% 
shrinkage) in one week (Figure 4.12B, blue inverted triangles).  
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Figure 4.10. Viability of LNCaP (red bars) and HEK-293 (cyan bars) cells in monolayer cultures. 
The confluent cells were treated with HBSS (control), folic acid, non-targeted polymersomes 
encapsulating Ca2+, targeted polymersomes encapsulating Ca2+, and targeted polymersomes 
encapsulating Ca2++ folic acid for 24 hours. Subsequently, the cell viability was determined 
employing the Alamar Blue assay (*P < 0.05, N = 6).  
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Figure 4.11. Cell viability analysis of LNCaP (red bars) and HEK-293 (cyan bars) spheroids. The 
7-day-old spheroids were treated with HBSS (control), folic acid, non-targeted polymersomes 
encapsulating Ca2+, targeted polymersomes encapsulating Ca2+, and targeted polymersomes 
encapsulating Ca2++ folic acid for 24 hours. Subsequently, the cell viability was determined 
employing the Alamar Blue assay (*P < 0.05, N = 6). 
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Figure 4.12. The growth curves for the HEK-293 and LNCaP spheroids. The 7-day-old spheroids 
of HEK293 cells (A), and LNCaP cells (B) were treated with HBSS buffer as a control (black 
squares), folic acid (red circles), targeted polymersomes encapsulating Ca2+ (green triangles), and 
targeted polymersomes encapsulating Ca2++ folic acid (blue inverted triangles) for 24 hours. The 
growth of the spheroids was monitored for a total of 15 days (N = 12). 
4.3.8. Loss of Mitochondrial Membrane Potential 
To determine the mechanism of cell death, we tested the possible loss of the mitochondrial 
membrane potential185. In this endeavor, we stained the LNCaP cells with TMRM dye, and 
analyzed the fluorescence intensity (Ex: 548 nm, Em: 574 nm) using flow cytometry. Loss of 
membrane potential can be recognized by the decreased TMRM fluorescence intensity186. We 
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observed that the cells treated with the targeted polymersomes encapsulating Ca2+ in the presence 
of folic acid showed lower fluorescence intensity compared to the control cells (treated with 
HBSS) (Figure 4.13). The reduced fluorescence intensity indicates that the loss of mitochondrial 
membrane potential is a possible mechanism for killing the cancer cells. Table 1 shows the mean 
fluorescence intensity of the TMRM stained cells measured with the FL2 channel of the flow 
cytometer.  
 
 
 
 
 
 
 
 
 
Figure 4.13. Flow cytometry analysis of LNCaP cells treated with the targeted polymersomes 
encapsulating Ca2++ folic acid to monitor TMRM-stained cells. Cells treated with formulation 
(B) are showing lower TMRM mean fluorescence compared to the cells treated with HBSS (C) 
indicating loss of mitochondrial membrane potential as a result of the treatment. Cells without 
staining are also shown (A). 
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4.4. Conclusion 
We have used folate presenting, reduction-sensitive polymersomes to actively target the 
prostate cancer cells overexpressing the PSMA receptor on the surface. The polymersomes 
encapsulate a high concentration of calcium chloride (50 mM). Releasing the CaCl2 in the cancer 
cell cytoplasm in presence of folic acid likely formed calcium phosphate crystals, dysregulation of 
calcium homeostasis, loss of the mitochondrial membrane potential, and cell death. We have not 
used any toxic anticancer drugs to induce the apoptosis of the cancer cells. This drug free treatment 
can offer new insights to target and kill the cancer cells by more biologically compatible 
compounds. 
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5. OVERALL SUMMARY AND FUTURE DIRECTIONS 
Employing the physiochemical differences between the cancer and normal cells can be a 
promising strategy to target the cancerous tissue. Targeted therapy can help in increasing the 
therapeutic index of anti-cancer drugs. Both extracellular and intracellular (cytosol and organelles 
including nucleus, mitochondria) environment can be used to effectively deliver the therapeutic 
agents to the cancer cells. Nanotechnology, chemistry, and biology are providing the required 
knowledge and tools to construct smart, stimuli responsive, targeted drug delivery systems. We 
successfully developed polymersome-based drug delivery vehicles to target the cancer cell nuclei. 
The vesicles have a PEG layer on the surface to minimize immunogenicity. PEGylation is known 
to decrease the interaction of the polymersomes with the immune cells and increases the circulation 
time of the nanoparticles3. Due to the presence of reduction sensitive polymers in the building 
block of polymersomes, they can be engineered to release their content at the intended target site 
while maintaining stability in the circulation. This delivery strategy can help in effective 
translocation of the toxic drug to the cell nucleus. To target the cell nuclei, we have used both 
small molecule (Chapter 2) and nuclear localizing peptide (Chapter 3). 
The EPR effect helps in accumulation of the polymersomes in the tumor site and acridine 
orange drives the polymersomes to the cell nuclei. Acridine orange is a small with an intrinsic 
affinity toward DNA. Hence, we have conjugated the acridine orange moiety to the surface of the 
polymersomes to target the cell nuclei. Following the internalization of the polymersomes in the 
cancer cell nuclei, they release their content (gemcitabine and doxorubicin) in response to the local 
high reducing agent concentration. Using this strategy, we have simultaneously delivered the 
chemotherapeutic agents gemcitabine and doxorubicin to the PANC-1 cells. The formulation 
showed significant toxicity to the cancer cells in both monolayer and 3D spheroid cultures. 
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Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is a nucleoside analog187 and doxorubicin is an 
intercalating agent188. Therefore, these two drugs induce apoptosis via different mechanisms. We 
have encapsulated both drugs in the polymersomes to simultaneously use both of these strategies 
against pancreatic cancer. 
The enzyme MMP-7 is overexpressed in the pancreatic cancer tumor microenvironment 
and aids in the progression of the disease. Hence, we designed an MMP-7 responsive peptide 
which is cleaved by the enzyme in the tumor microenvironment. This hydrolysis unmasks the 
nuclear localizing peptide, which mediates the polymersomes’ nuclear internalization. The 
polymersomes are designed to release their content in response to high reducing agent 
concentration in cell nuclei. We successfully delivered doxorubicin and curcumin to the nuclei of 
pancreatic cancer cells (BxPC-3 and AsPC-1). The formulation shrunk the pancreatic cancer 
microtumores without much toxicity to the non-cancerous cells. Curcumin is a natural product, 
which has shown considerable promises against several types of cancers.  Doxorubicin is an FDA-
approved chemotherapeutic agent against cancer. We have simultaneously used these two 
compounds to kill the pancreatic cancer cells.  
Prostate specific membrane antigen (PSMA) is overexpressed on the surface of prostate 
cancer cells. This receptor can be targeted by folic acid. Hence, we used folic acid conjugated 
polymersomes to actively target the prostate cancer cells. To develop a safer anticancer 
formulation, we encapsulated the polymersomes with a high concentration of CaCl2. The 
polymersomes specifically enter the prostate cancer cells through interaction with the PSMA on 
the cell surface. The formulation is designed to release its content in the cell cytoplasm where the 
reducing agent concentration is higher than the extracellular matrix. Release of a large amount of 
calcium ions in the cytoplasm in the presence of folic acid triggers the formation of calcium micro-
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crystals, which causes cancer cell death through apoptosis. We have tested this formulation on 
prostate cancer cells (LN-CaP) in both two and three-dimensional culture. Testing the formulation 
on animal model would help to demonstrate polymersomes’ effectiveness evaluation in vivo. 
Results of this study suggest the potential use of biocompatible resources to combat cancer.  
Considering the progress in developing polymersomes as theranostic nanovesicles, it is 
envisioned that polymersomes will play an important role as future pharmaceuticals. However, it 
should be noted that these formulations have some drawbacks. A low drug-loading efficiency, the 
presence of toxic, residual organic solvents in the final product, a lack of specificity toward the 
target site, and non-efficient control of the payload release need to be addressed. Therefore, future 
studies should focus on the preparation methods, which are free of organic solvents, can be scaled 
up, and possess efficient targeting, and release properties. Although many studies demonstrate the 
effectiveness of polymersomes in mice or rats, shifting toward species that are evolutionarily 
closer to humans may accelerate the translational processes. To increase selectivity, polymersomes 
are usually decorated with ligands for cell-surface receptors of target tissues. However, differences 
in human’s genetic contents and a lack of expression for some receptors in different patients need 
to be considered 189. Another important factor that warrants more attention is the polymersomes’ 
pharmacokinetics. For long-term administration, the polymersomes’ toxicity on vital organs needs 
to be studied. 
Paper information: Polymersome-based drug-delivery strategies for cancer therapeutics (Ther. 
Deliv. (2015) 6(4), 521–534). 3 
https://www.ncbi.nlm.nih.gov/pubmed/25996048 
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APPENDIX A. SUPPORTING INFORMATION FOR CHAPTER 2  
A1. Confocal Fluorescence Microscopic Images of PANC-1 Cells 
 
Figure A1. Confocal fluorescence microscopic images of nuclear localization of AO-
polymersomes in PANC-1 cells without dexamethasone pre-treatment. (A) Bright field 
microscopy image; (B) Hoechst stained nuclei of the cells (DAPI filter); (C) image recorded with 
FITC filter (the green color is showing the AO location); (D) image recorded using TRITC filter 
(the red color is showing the presence of lissamine rhodamine); and (E) overlayed images (scale 
bars: 200 µm). 
A2. ESI Mass Spectrum of the Alkyne Conjugated Acridine Orange 
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Figure A2. ESI mass spectrum of the alkyne conjugated acridine orange.  The calculated molecular 
mass is: 361.2 
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A3. Absorbance Spectra of Polymersomes Before and After Size Exclusion 
Chromatography 
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Figure A3. Absorbance spectra of the drug-encapsulated polymersomes before (black trace), and 
after (red trace) size exclusion chromatography.  
A4. Images of Spheroid Cell Cultures at Multiple Focal Planes      
Legend for Movie: 
The link for the short video that we have obtained by confocal microscopy from multiple focal 
planes of an 8-day old spheroid: https://youtu.be/qxj6hkeghgs 
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APPENDIX B. SUPPORTING INFORMATION FOR CHAPTER 3 
B1. Peptide Purification and Characterization 
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Figure B1. Peptide purification and characterization using RP-HPLC and MS spectrometry. (A) 
RP-HPLC chromatogram of the crude peptide (the marked peak is showing the pure peptide 
fraction). (B) MS analysis of purified peptide (calculated exact mass: 2204.16). 
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B2. Captisol-Curcumin Complexation 
 
Figure B2. Curcumin-Captisol complexation. Curcumin amount was kept constant (25 mg). 
Increasing the concentration of captisol in water from 0 to 40% (W/V) increased the solubility of 
curcumin. The complexation was carried out at room temperature for 3 days. 
 
 
 
 
 
 
 
 
 119 
 
B3. Calibration Curve for Measuring Curcumin Concentration 
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Figure B3. Calibration curve for measuring the curcumin concentration. Absorbance was recorded 
at 429 nm. 
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B4. Drug Encapsulation in Polymersomes 
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Figure B4. Drug encapsulation in polymersomes. (A) The presence of a peak at 420 nm is 
indicating the presence of the Captisol-curcumin complex in the polymersomes’ aqueous core. The 
red trace is indicating the Captisol-curcumin complex absorption spectra, and the black trace is 
showing absorption spectra of polymersomes encapsulating curcumin complex. (B) The 
absorption spectra of the polymersomes encapsulating doxorubicin before (black trace), and after 
(red trace) size exclusion chromatography shows the presence of doxorubicin in the vesicles.  
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B5. Calcein Release from the Polymersomes in the Presence of MMPs 
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Figure B5. The release of calcein from the polymersomes in the presence of added MMP-7, MMP-
9, and MMP-1 enzyme (2 µM each). Calcein release was monitored for 30 minutes in the presence 
of added MMP-9 (black trace), MMP-7 (blue trace), and MMP-1 (red trace).  
B6. Growth Curves for the AsPC-1 Cell Spheroids 
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Figure B6. Growth curves for the AsPC-1 cell spheroids. The 8-day old spheroids were treated 
with different polymersome formulations, and their growth was monitored for 10 days (N = 8). 
Black trace with squares: plain polymersomes; red trace with circles: curcumin and doxorubicin 
encapsulated polymersomes; blue trace with triangles: curcumin and doxorubicin encapsulated, 
peptide conjugated polymersomes; magenta trace with inverted triangles: free drug combination. 
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B7. Cell Viability of Three-dimensional Spheroids (AsPC-1 cells) 
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Figure B7. Cell viability of three-dimensional spheroids (AsPC-1 cells) after treatment with 
different polymersome formulations (N = 6). 
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APPENDIX C. SUPPORTING INFORMATION FOR CHAPTER 4 
C1.  Formation of Calcium Phosphate Crystals in the Cell Culture Media 
 
 
 
 
 
 
 
 
 
Figure C1.  Formation of calcium phosphate crystals in the cell culture media (marked with the 
white arrows) in the presence of folic acid (500 µg/mL) and CaCl2 (50 mM). RPMI-1640 complete 
growth medium supplemented with fetal bovine serum (10%), and antibiotic-antimycotic solution 
(1%) was used.  Magnification: 20X. 
C2. Calibration Curve for Measuring the Concentration of Polymersome-Encapsulated Ca2+ 
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Figure C2. Calibration curve for measuring the concentration of polymersome-encapsulated Ca2+. 
The squares are showing the observed data points, while the Red line is showing the fitted straight 
line. 
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C3.  Calcein Release from the Polymersomes in the Absence of GSH 
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Figure C3.  Calcein release from the polymersomes in the absence of GSH. The release was 
monitored for 80 minutes. 
 
 
 
 
 
 
